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Abstract 
 
Peptide and protein drugs are highly versatile with numerous therapeutic properties such as anti-cancer, 
anti-diabetic, anti-hypertensive, and anti-microbial; which are therefore ideal candidates for the 
development of next-generation drugs. This is exemplified using these drugs for the treatment of diseases 
such as diabetes. Diabetes is one of the most prevalent non-communicable diseases worldwide. The rapid 
increase in the number of diabetic patients globally places a burden on current insulin manufacturers. The 
traditional reversed-phase high-performance liquid chromatography (RP-HPLC) purification methods of 
insulin and peptides are problematic, tedious with long run times of approximately 50 minutes, low yields 
employ harsh solvents such as acetonitrile, which has a negative impact on the environment. There is a 
need for a greener process for the purification of insulin and peptides. Sub/supercritical fluid 
chromatography (SFC) can provide the solution since it utilises greener mobile phases such as carbon 
dioxide (CO2) and methanol, which can be recycled. However, there is a paucity of knowledge regarding 
the SFC purification of human insulin and peptides. Therefore, this research study aimed to provide an 
efficient, innovative approach for the biosynthesis of human insulin and the SFC purification of 
biosynthesised human insulin, as well as the extension into the SFC purification of peptides. The 
background of these topics is presented in Chapter One. 
 
Chapter two (manuscript one) presents the development of a novel and more efficient method of human 
insulin biosynthesis in Escherichia coli (E. coli). Several of the conventional steps were eliminated. The 
crude biosynthesised protein sequence was verified using protein sequencing, which had a 100% 
similarity to the human insulin sequence. The biological activity of the biosynthesised human insulin was 
tested in vitro using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. The 
biosynthesis of human insulin was conducted on a laboratory-scale basis; future studies should investigate 
scaling up of this method. 
 
Chapter three (manuscript two) was based on the SFC purification of the commercially available standard 
sample of human insulin and a crude biosynthesised sample of human insulin. The SFC purified standard 
the biosynthesised human insulin samples were detected and quantified using liquid chromatography-
mass spectrometry (LC-MS) and protein sequencing techniques. SFC columns, i.e., silica, 2’ ethyl 
pyridine, diol-HILIC, and the pentafluoro phenyl (PFP), were evaluated to determine the ideal column. 
The PFP column gave the best results since it displayed good peak shapes, resolution, retention factors, 
retention times, and the least relative standard deviation in comparison to the other columns. Therefore, 
the aforementioned column was selected for further analysis using the biosynthesised human insulin, 
whereby a column efficiency test was conducted on a semi-preparative scale, yielding 84% recovery. 
Subsequently, the biological activities of the SFC purified standard sample of human insulin and 
biosynthesised version were tested in vitro using a MTT assay. The results indicated that the biological 
activities of the standard and biosynthesised human insulin derivatives were retained subsequent to SFC 
purification. The biological activities were highly significant, with a p-value of < 0.0001. 
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From chapter three, band broadening and phase separation peaks were experienced during SFC 
purification of the commercially available standard sample of human insulin and biosynthesised human 
insulin. Therefore, in Chapter four (manuscript three), a SFC purification method was developed to purify 
peptides at an analytical scale. A tetrapeptide [insulin β chain peptide (15-18)], octapeptide [angiotensin 
II], nonapeptide [insulin β chain peptide (15-23)] were purified using four SFC columns, i.e., PFP, diol-
HILIC, silica, and 2’ ethyl pyridine. Subsequently, the 2’ ethyl pyridine column was selected for further 
analysis based on the reproducibility, peak shapes, efficient separations and retention factors. The three 
peptides were monitored using LC-MS analysis. The successful peptide recoveries ranged from 80-102%.  
 
Chapter five pertains to the summary and conclusion drawn from the study and reflects on possible future 
endeavours. The present study was successful in providing a more affordable and innovative approach for 
the biosynthesis of human insulin. The work also successfully developed a rapid, greener, and more 
efficient method of SFC purifying biosynthesised human insulin and peptides as opposed to conventional 
HPLC purification methods. As far as we are aware, this study is the first of its kind to purify 
biosynthesised human insulin and this combination of peptides using SFC purification techniques. Future 
research studies can focus on the SFC purification of larger protein molecules and consider the use of 
custom columns and or other modifiers for the improvement of the isolation of other highly sought after 
biologics within the pharmaceutical industry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Declaration 1-Plagiarism 
 
I, Miss Kamini Govender declare that 
  
1. The research reported in this thesis, except where otherwise indicated, and is my original 
research. 
2. This thesis has not been submitted for any degree or examination at any other university. 
3. This thesis does not contain other persons’ data, pictures, graphs or other information unless 
specifically acknowledged as being sourced from other persons. 
4. This thesis does not contain other persons’ writing unless specifically acknowledged as being 
sourced from other researchers. Where other written sources have been quoted, then: 
a. Their words have been re-written, but the general information attributed to them has been 
referenced  
b. Where their exact words have been used, then their writing has been placed in italics and 
inside quotation marks and referenced. 
5. This thesis does not contain text, graphics or tables copied and pasted from the internet unless 
specifically acknowledged and the source being detailed in the thesis and in the reference 
sections. 
 
 
 
 
Signature ………………………………… 
 
Miss Kamini Govender 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Declaration 2-Publications 
 
Detail of contribution to the publications that form part and/or include research presented in this 
dissertation (include publications in preparation, submitted, in press and published and give details of the 
contributions of each author to the experimental work and writing of each publication)  
 
List of publications: 
 
1) Kamini Govender
1
, Tricia Naicker
1
, Johnson Lin
2
, Sooraj Baijnath
1
, Anil Amichund Chuturgoon
3
, 
Naeem Sheik Abdul
3
, Taskeen Docrat3, Hendrik Gerhardus Kruger1* and Thavendran Govender4* 
 
A novel and more efficient biosynthesis approach for human insulin production in Escherichia coli 
(E. coli). AMB Express. Published, 2020. DOI: 10.1186/s13568-020-00969-w 
 
Kamini Govender biosynthesised human insulin using recombinant DNA technology, conducted, 
analysed all the experimental data and composed the entire manuscript including the supporting 
information. Taskeen Docrat, Dr Naeem Sheik Abdul and Prof. Anil Amichund Chuturgoon conducted 
the MTT assay. The rest of the authors are supervisors on the project and contributed to the 
conceptualisation of the idea and funding of the project. 
 
2) Kamini Govender
1
, Tricia Naicker
1
, Sooraj Baijnath
1
, Anil Amichund Chuturgoon
2
, Naeem Sheik 
Abdul
2
, Taskeen Docrat
2
, Hendrik Gerhardus Kruger
1*
 and Thavendran Govender
3* 
 
Sub/supercritical fluid chromatography employing a water-rich modifier enables the purification of 
biosynthesized human insulin. Journal of Chromatography B: Analytical Technologies in the 
Biomedical and Life Sciences, Accepted, 2020. DOI: 10.1016/j.jchromb.2020.122126. 
 
Kamini Govender biosynthesised human insulin using recombinant DNA technology and developed a 
cost-effective method for the SFC purification of human insulin, analysed all the experimental data and 
composed the entire manuscript, including the supporting information. Taskeen Docrat, Dr Naeem Sheik 
Abdul and Prof. Anil Amichund Chuturgoon conducted the MTT assay. The rest of the authors are 
supervisors on the project and contributed to the conceptualisation of the idea, funding of the project, and 
provided scientific guidance. 
 
 
 
 
v 
 
3) Kamini Govender
 1
, Tricia Naicker
1
,
 
Sooraj Baijnath
 1
,
 
Hendrik Gerhardus Kruger
1*
 and Thavendran 
Govender
2* 
 
The development of a sub/supercritical fluid chromatography-based purification method for 
peptides. Journal of Pharmaceutical and Biomedical Analysis, Submitted, 2020.  
 
Kamini Govender developed an efficient and cost-effective method for the SFC purification of peptides, 
analysed all the experimental data and composed the entire manuscript including the supporting 
information. The rest of the authors are supervisors on the project and contributed to the conceptualisation 
of the idea, funding of the project, and provided scientific guidance. 
 
Other publications which I contributed to: 
 
Satheesh Natarajan
1
,
 
Kamini Govender
1
, Mokgokong Makwena
1
, Sooraj Baijnath
1
, 
 
Adeola Shobo
1
, Per I 
Arvidsson
1,2
, Thavendran Govender
1
, Johnson Lin
3
, Glenn Maguire
1,4
, Tricia Naicker
1
, Gert Kruger1* and 
Rae Silver
5*  
 
Potential of brain mast cells for therapeutic application in the immune response to bacterial and 
viral infections. Submission in progress. 
 
Sateesh Natarajan and Kamini Govender, contributed to manuscript preparation, literature search, editing 
and writing of the manuscript. Mokgokong Makwena contributed to a literature search of the manuscript. 
Adeola Shobo contributed to a literature search and writing of the manuscript. The rest of the authors are 
supervisors on the project and contributed to the conceptualisation of the idea, funding of the project, and 
provided scientific guidance. 
 
 
 
 
 
Signature ………………………………… 
 
Miss Kamini Govender 
 
 
 
 
 
 
vi 
 
Dedication 
 
This thesis is dedicated to my wonderful parents, Parma Varadarajalu Govender and Maeshwari 
Govender as well as my sister, Sovishnee Govender. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Acknowledgements 
 
I wish to express my sincere gratitude and appreciation to the following persons and institutions: 
 
 I would like to thank God for giving me the strength, determination and perseverance throughout 
this study.  
 
 To my parents, Parma and Maeshwari, thank you for your support and always inspiring me to be 
the best that I can be; I appreciate every sacrifice and endeavour that you have made throughout 
my studies. I could not have asked for better parents. Thank you for your love and support, which 
has allowed me to achieve my goals.  
 
 I would like to thank my awesome sister, Sovishnee, for being a wonderful sister and for her 
encouragement throughout my studies. You are a true inspiration and my superhero. 
 
 To my supervisors, Prof. T. Govender, Prof. H. G. Kruger, and Prof. T. Naicker, thank you for 
your guidance, support and excellent supervision throughout this study. Thank you for leading 
and inspiring the fourth revolution of industrial scientists in drug discovery.  
 
 I would like to thank Prof. Tricia Naicker for her patience, assistance, and guidance. Thank you 
for your expert advice in the lab that enabled me to become a better Ph.D. student. I appreciate all 
the help you have given me throughout this study.  
 
  I would also like to thank Prof. Gert Kruger for all of his time and expert opinion. He is 
dedicated and I appreciate all your help throughout this study. I truly respect and value your 
advice; I hope that one day I can have as many publications as you. 
 
 I would like to thank Dr Sooraj Baijnath and Prof. Lin for their time, assistance, and 
guidance. I appreciate all the help given to me throughout this study.  
 
 To Prof. Thavi Govender, I humbly thank you for conceptualizing this project. I sincerely thank 
you for allowing me to conduct this research for my Ph.D. project. Thank you for introducing me 
to the field of SFC purification. I appreciate all your help, guidance and assistance throughout my 
project.  
 
 
 
viii 
 
 To all my research colleagues at the Catalysis and Peptide Research Unit (CPRU): Nakita, Arno, 
Lloyd, Kim, Shimaa, Sibusiso, Kamal, Spha, Neliswa, Mbo, Leon, Advaitaa, Sane and Yahya 
thank you for your support and friendship throughout this study. Especially for creating a 
wonderful work environment conducive to research. 
 
 I would like to acknowledge the Central Analytical Facility (Stellenbosch University, South 
Africa) for conducting the protein sequencing. 
 
 This work was made possible through financial support from the National Research Foundation 
(NRF) and the Technology Innovations Agency (TIA) of South Africa. 
 
 This work was made possible through the University of KwaZulu-Natal (Westville) as I used the 
University’s equipment and premises throughout this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
Abbreviations 
 
Å   Angstrom 
aa   Amino acid 
Anova   Analysis of variance 
BPR   Back pressure regulator 
C terminal  Carboxyl terminal 
CHCA   Alpha-cyano-4-hydroxycinnamic acid 
Co
2+
   Cobalt ion 
CO2   Carbon dioxide 
cRAP   Contaminant protein database 
Cu 
2+
   Copper ion 
Da   Dalton 
°C   Degrees Celsius 
DCCA   Diabetes control and complications trial 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
E. coli   Escherichia coli 
FA   Formic acid 
g   Grams 
GST   Glutathione S-transferase 
HCCA   Alpha-cyano-4-hydroxycinnamic acid 
HepG2   Hepatocellular carcinoma 
HFIP   Hexafuoroisopropanol 
HG   Hyperglycaemic 
HILIC   Hydrophilic interaction liquid chromatography 
HNF1a   Hepatic nuclear transcription factor 
125
I   Radioisotope of iodine 
ID   Internal diameter 
IDF   International diabetes federation  
IEC   Ion exchange chromatography 
IMAC   Immobilized metal affinity chromatography 
IPF-1   Insulin promotor factor-1 
IPTG   Isopropyl β-D thiogalactoside 
IU   International units 
k   Retention factor 
kb   Kilo-base 
 
x 
 
kDa   Kilo-dalton 
kV   Kilovolt 
L   Litre 
LB   Luria-bertani 
LC-MS   Liquid chromatography-mass spectrometry 
μL   Micro litre 
μg   Microgram 
μm Micrometre 
MALDI-TOF-MS Matrix-assisted laser desorption ionisation-time of flight-mass spectrometry 
mg   Milligram 
mL   Millilitre 
mm   Millimetre 
mM    Millmolar 
MS   Mass spectrometry 
MS/MS   Tandem mass spectrometry 
MTT   3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
m/z   mass to charge ratio 
ng   Nanograms 
NG   Normoglycaemic 
Ni   Nickel 
Ni
2+   
Nickel ion 
NCD   Non-communicable disease 
nm   Nanometre 
Nr   Not retained  
N terminal  Amino terminal 
NTA   Nitrilotriacetic acid 
OD   Optical density  
%   Percent 
p-value   Calculated probability 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDA   Photodiode array 
PFP   Pentafluoro phenyl 
pI   Isoelectric point 
RIA   Radioimmunoassay 
RP-HPLC  Reversed phase-high performance liquid chromatography 
rpm   Revolutions per minute 
 
xi 
 
SDS-PAGE  Sodium dodecyl sulphate poly-acrylamide gel electrophoresis 
SEC   Size exclusion chromatography 
SFC   Sub/supercritical fluid chromatography 
TEV   Tobacco Etch Virus 
TFA   Trifluoroacetic acid 
tRNA   Transfer ribonucleic acid 
USA   United States of America 
USP   United States Pharmacopeia 
UV   Ultraviolet 
WHO   World Health Organization 
Zn
2+
   Zinc ion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Figures 
 
Figures from Chapter 1. 
 
Figure 1: Insulin structure depicting polypeptide chains A and B, the A chain is depicted in brown, the B 
chain is depicted in blue, and the disulphide bonds are depicted in green, adapted from [60] (open access).
 .......................................................................................................................................................................7 
Figure 2: (A) An illustration of a T-state monomer of insulin with secondary and tertiary structures, B1-
B8 region in an extended conformation. The A-chain is depicted in grey, and the B-chain is blue. (B) An 
illustration of a T-state dimer of insulin with secondary and tertiary structures. The A-chain is depicted in 
grey, and the B-chain is blue and cyan. (C) An illustration of secondary and tertiary structures of insulin 
in a T-state hexamer. The A-chain is depicted in grey, and the B-chain is blue and cyan with zinc depicted 
in green. (D) A representation of secondary and tertiary structures of insulin as an R-state hexamer in the 
presence of preservative. The A-chain is depicted in grey, and the B-chain is blue and cyan with zinc 
depicted in green, and the preservative is represented in magenta, picture adapted from [61]. ....................8 
Figure 3: A schematic diagram of an HPLC system [111] (open access). .................................................13 
Figure 4: CO2 phase diagram adapted from [116]......................................................................................14 
Figure 5: A schematic representation of a typical SFC flow path [119] (open access). .............................14 
Figure 6: MALDI-TOF-MS sample ionisation process [141]. ...................................................................16 
 
Figures from Chapter 2. 
 
Figure 1: Images displaying the PCR amplicons of proinsulin DNA, purified vector DNA, and the 
integrated pET21b-hPin vector with the inserted proinsulin gene. Lanes 1 and 12 contain one kb 
molecular weight marker. Lanes 2 to 7 contains the PCR amplicons of proinsulin flanked with BamHI 
and XhoI restricted ends; Lane 8 contains the purified pET21b miniprep product; Lanes 9 to 11 contain 
the integrated pET21b-hPin vector miniprep products................................................................................39 
Figure 2: A MALDI-TOF spectrum illustrating the supernatant sample of crude biosynthesised human 
insulin, which was induced at 1 mM IPTG. ................................................................................................40 
Figure 3: A peptide spectrum illustrating the protein sequence of crude biosynthesised human insulin, 
which was a 100% match to the human insulin sequence derived from the Scaffold 1.4.4 software. ........41 
Figure 4: A graph illustrating the cell viability of HepG2 cells, under hyperglycaemic conditions for 
standard and crude biosynthesised human insulin at low (50 ng/mL), medium (100 ng/mL) and high (150 
ng/mL) MTT concentrations (p-value < 0,0001). .......................................................................................42 
 
 
 
 
xiii 
 
Figures from Chapter 3. 
 
Figure 1: Represents SFC chromatograms of the standard sample of insulin (1 mg/mL) on analytical size 
columns (250 mm × 4.6 mm): (A) silica column (B) 2’ethyl pyridine (C) diol-HILIC (D) PFP. All 
columns were run using a gradient mode with a modifier range of 5-60%. ................................................58 
Figure 2: A Represents a LC-MS spectrum obtained from a YMC-Triart C18 (dimensions: 150 mm × 4.6 
mm (length x internal diameter), pore size: 120 Å, and a particle size of 5 μm) of the crude biosynthesised 
sample of insulin and B represents SFC chromatograms of the crude biosynthesised sample of insulin, 
which was separated on a PFP based column with the following characteristics; dimensions: 250 mm × 
4.6 mm (length x internal diameter), pore size: 120 Å and a particle size of 5 μm.....................................60 
Figure 3: Represents a LC-MS spectrum obtained from a YMC-Triart C18 (dimensions: 150 mm × 4.6 
mm (length x internal diameter), pore size: 120 Å, and a particle size of 5 μm) of SFC purified 
biosynthesised sample of insulin. ................................................................................................................60 
Figure 4: A peptide spectrum illustrating  the standard sample of insulin, which had a 90% peptide 
sequence probability to human insulin derived from the Scaffold 1.4.4 software (Central Analytical 
Facility, Stellenbosch University, South Africa) [42]. ................................................................................60 
Figure 5: A peptide spectrum illustrating the biosynthesised sample of insulin after SFC purification with 
a 96% probability in peptide sequence to human insulin derived from the Scaffold 1.4.4 software (Central 
Analytical Facility, Stellenbosch University, South Africa) [42]. ..............................................................61 
Figure 6: A graph displaying the cell viabilities of HepG2 cells, under normoglycaemic (NG) and 
hyperglycaemic (HG) conditions for low (50 ng/mL), medium (100 ng/mL) and high (150 ng/mL) MTT 
concentrations treated with standard insulin sample before SFC purification and after SFC purification (p-
value < 0.0001). ...........................................................................................................................................62 
Figure 7: A graph displaying the cell viabilities of HepG2 cells, under normoglycaemic (NG) and 
hyperglycaemic (HG) conditions under low (50 ng/mL), medium (100 ng/mL) and high (150 ng/mL) 
MTT concentrations treated with biosynthesised insulin sample before SFC purification and after SFC 
purification (p-value < 0.0001). ..................................................................................................................63 
 
Figures from Chapter 4. 
 
Figure 1: Represents 50 μL injections of SFC chromatograms of tetra-peptide (1 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl pyridine 
(250 mm × 4.6 mm), D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were tested on a gradient 
mode with a modifier range of 5-60%. ........................................................................................................77 
Figure 2: Represents a 50 μL injection of a SFC chromatogram of the tetrapeptide (1 mg/mL) tested on a 
2’ ethyl pyridine column-based column with the following characteristics; dimensions: 250 mm× 10 mm, 
 
xiv 
 
pore size: 300 Å and a particle size of 5 μm. It was conducted on a gradient mode with a modifier range 
of 5-60%. .....................................................................................................................................................78 
Figure 3: Represents 50 μL injections of SFC chromatograms of the octapeptide (2 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl pyridine 
(250 mm × 4.6 mm), and D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were tested on a gradient 
mode with a modifier range of 5-60%. ........................................................................................................79 
Figure 4: Represents 50 μL injections of SFC chromatograms of nonapeptide (1.5 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl pyridine 
(250 mm × 4.6 mm), and D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were conducted on a 
gradient mode with a modifier range of 5-60%. ..........................................................................................80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
List of Tables 
 
Tables from Chapter 2 
 
Table 1: The concentrations of human insulin obtained for the IPTG induction calculated based on 
commercial human insulin. 40 
 
Tables from Chapter 3 
 
Table 1: Retention factors (k) of the standard sample of insulin (1 mg/mL). 58 
 
Tables from Chapter 4 
 
Table 1: Molecular weight and sequences of crude peptides used in this study .........................................73 
Table 2: Physical dimensions of SFC columns employed in this study .....................................................74 
Table 3: Retention factors (k) of the tetrapeptide (1 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, and 
PFP columns. ...............................................................................................................................................80 
Table 4: Retention factors (k) of the octapeptide (2 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, and 
PFP columns conducted at 5-60% gradient conditions. ..............................................................................81 
Table :5 Retention factors (k) of the nonapeptide (1.5 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, and 
PFP columns conducted at 5-60% gradient conditions. ..............................................................................81 
Table 6: Reproducibility of retention times (n=3) for the separation of a tetrapeptide (1 mg/mL) [insulin β 
chain peptide (15-18)], octapeptide (2 mg/mL) [angiotensin II], nonapeptide (1.5 mg/mL) [insulin β chain 
peptide (15-23)]. Conducted on a 2’ ethyl pyridine column (250 mm × 10 mm). Conducted on a gradient 
mode with a modifier range of 5-60%. ........................................................................................................82 
Table 7: Represents the recoveries of the tetrapeptide, octapeptide, and the nonapeptide post-SFC 
purification. Peptide recoveries were conducted on the SFC using 5 mg samples (whereby n=1). ............83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
Table of contents 
 
Abstract ........................................................................................................................................................ i 
Declaration 1-Plagiarism .......................................................................................................................... iii 
Declaration 2-Publications........................................................................................................................ iv 
Dedication .................................................................................................................................................. vi 
Acknowledgements ................................................................................................................................... vii 
Abbreviations ............................................................................................................................................. ix 
List of Figures ........................................................................................................................................... xii 
List of Tables ..............................................................................................................................................xv 
Table of contents ...................................................................................................................................... xvi 
Chapter 1 ......................................................................................................................................................1 
Literature review .........................................................................................................................................1 
1.1 The prevalence of diabetes ..............................................................................................................2 
1.2  Diabetes mellitus ..............................................................................................................................3 
1.2.1 Type one diabetes ........................................................................................................................3 
1.2.2. Type two diabetes ........................................................................................................................4 
1.2.3 Gestational diabetes ....................................................................................................................4 
1.2.4 Genetic defects of beta-cell function and insulin action ...........................................................4 
1.2.5 Diseases of the exocrine pancreas and endocrinopathies .........................................................5 
1.2.6 Drug-induced and infections that cause diabetes .....................................................................6 
1.2.7  Genetic and metabolic syndromes associated with diabetes ...................................................6 
1.3 The structure of insulin ...................................................................................................................7 
1.4  Methods of verifying the biological activity of insulin ................................................................8 
1.5  Polymerase chain reaction (PCR) ..................................................................................................9 
1.6 The biosynthesis of insulin using recombinant DNA technology ................................................9 
1.7 The use of affinity tags in protein purification ...........................................................................10 
1.8 Traditional methods for insulin purification ..............................................................................12 
1.9  SFC purification ...........................................................................................................................13 
1.10  Purification of peptides ................................................................................................................15 
1.11  Matrix-assisted laser desorption ionisation-time of flight mass spectrometry .......................16 
1.12  Protein sequencing ....................................................................................................................17 
1.13  Aims and objectives of the study .................................................................................................18 
1.14  Outline of thesis ............................................................................................................................18 
 
xvii 
 
1.15  References .....................................................................................................................................19 
Chapter 2 ....................................................................................................................................................31 
A novel and more efficient biosynthesis approach for human insulin production in Escherichia coli 
(E. coli). .......................................................................................................................................................32 
Abstract ......................................................................................................................................................33 
1 Introduction .......................................................................................................................................34 
2 Materials and methods ......................................................................................................................35 
3 Results ................................................................................................................................................39 
4 Discussion and conclusion .................................................................................................................42 
5 Acknowledgements ............................................................................................................................45 
6 Conflict of interest .............................................................................................................................45 
7 Author’s contribution .......................................................................................................................46 
8 References ..........................................................................................................................................46 
Chapter 3 ....................................................................................................................................................49 
Sub/supercritical fluid chromatography employing a water-rich modifier enables the purification of 
biosynthesised human insulin. ..................................................................................................................50 
Abstract ......................................................................................................................................................51 
1 Introduction .......................................................................................................................................52 
2 Materials and methods ......................................................................................................................53 
3 Results and discussion .......................................................................................................................56 
4 Conclusion ..........................................................................................................................................63 
5 Acknowledgements ............................................................................................................................64 
6 Conflict of interest .............................................................................................................................64 
7 Authors contribution .........................................................................................................................64 
8 References ..........................................................................................................................................64 
 ....................................................................................................................................................68 Chapter 4
The development of a sub/supercritical fluid chromatography-based purification method for 
peptides. ......................................................................................................................................................69 
Abstract ......................................................................................................................................................70 
1 Introduction .......................................................................................................................................71 
2 Materials and methods ......................................................................................................................73 
3 Results and discussion .......................................................................................................................75 
4 Conclusion ..........................................................................................................................................83 
5 Acknowledgments ..............................................................................................................................83 
6 Conflict of interest .............................................................................................................................84 
 
xviii 
 
7 Authors contribution .........................................................................................................................84 
8 References ..........................................................................................................................................84 
 ....................................................................................................................................................90 Chapter 5
5 Summary and conclusion ..................................................................................................................91 
 .................................................................................................................................................94 Appendices
 .........................................................................................................................95 Appendix 1 for Chapter 2
 .......................................................................................................................101 Appendix 2 for Chapter 3
 .......................................................................................................................106 Appendix 3 for Chapter 4
 
 
 
 
1 
 
 
 
 
Chapter 1 
 
 
Literature review 
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1.1 The prevalence of diabetes  
 
Diabetes is a non-communicable disease (NCD) that occurs when the pancreas is incapable of 
producing enough insulin or when the body cannot effectively utilise the insulin it produced [1-3]. 
Diabetes is considered a global health problem because it is a prevalent non-communicable disease. 
The number of cases and prevalence of diabetes has steadily increased over the past few decades [1, 
4]. 
 
In 2014 approximately 422 million adults were living with diabetes, in comparison to 108 million in 
1980 [1, 2, 4]. In 2017 it was estimated that 451 million people between the ages of 18-99 years 
suffered from diabetes [5, 6]. In 2019 approximately 463 million adults suffered from diabetes 
globally, and 19 million are from Africa. It was estimated that in 2045, the number of people with 
diabetes would rise to 700 million [5-7]. Concerning the prevalence of diabetes in South Africa, in 
2017, it was reported that 1.8 million people suffered from diabetes [7]. However, in 2019 the 
international diabetes federation (IDF) reported that approximately 4.5 million people were living 
with diabetes in South Africa, the rapid increase of people suffering from diabetes in South Africa has 
placed the country on the top 10 countries for an alarming increase in diabetes prevalence [7]. The 
drastic increase in the number of diabetic patients globally places a burden on current insulin 
manufacturers. As a result, they would be unable to meet the growing demand for affordable insulin 
because of limitations in production capacity and high production costs [8, 9]. This research study 
aims to biosynthesise human insulin using recombinant DNA technology and provide an innovative 
greener purification method using Sub/supercritical fluid chromatography (SFC). 
 
The lack of access to affordable insulin eventually results in the premature death of diabetic patients 
[1, 10-12]. In 2012, there were approximately 3.7 million deaths related to blood glucose levels [1]. 
2.2 Million deaths were associated with increased risk of cardiovascular as well as other diseases, and 
approximately 1.5 million deaths occurred amongst people that were diagnosed with diabetes [1]. 
These deaths are caused by the lack of access to affordable human insulin [1]. There is a need for 
access to a more affordable and greener process to manufacture insulin. Currently, there is no cure for 
diabetes; however, this metabolic disorder can be managed using insulin or oral medication [13]. This 
study will use recombinant DNA technology to biosynthesise human insulin that provides a greener 
and more affordable purification strategy. The following section provides more information regarding 
diabetes mellitus. 
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1.2  Diabetes mellitus  
 
Diabetes mellitus is referred to as a metabolic disorder associated with complex aetiology [1, 2, 14]. 
This metabolic disorder is characterized by chronic hyperglycaemia associated with atypical fat, 
carbohydrate, and protein metabolism, which is as a result of defective insulin secretion. Diabetes 
causes severe long-term damage and, eventually, the failure of several organs [1, 2, 13, 15]. The long-
term side effects of diabetes mellitus are retinopathy with potential blindness, neuropathy, and 
nephropathy [1, 2, 4, 13, 15]. People suffering from diabetes are also at a higher risk of 
cerebrovascular, cardiovascular, and peripheral vascular disease [1, 2, 11, 13, 15, 16]. 
 
The development of diabetes is triggered by numerous pathogenetic processes. As such, these 
processes destroy the beta cells of the pancreas resulting in insulin deficiency, whereas others result in 
the resistance to insulin action [15, 17]. The anomalies in fat, protein, and carbohydrate metabolisms 
result in an inability of insulin to target tissues due to the lack of insulin or insensitivity of insulin 
[15]. 
 
Diabetes can be diagnosed based on the amount of glucose found in blood plasma, which can be 
detected after a fasting plasma glucose test, two-hour plasma glucose (oral glucose tolerance test), or 
an A1C test. A fasting plasma glucose test can be defined when there is no caloric intake for 
approximately eight hours. The criterion for the diagnosis of diabetes is if the fasting plasma glucose 
is ≥ 7.0 mmol/L (126 mg/dL) [1, 18]. The glucose tolerance test is conducted with an anhydrous 
glucose load of 75 grams, and after a two-hour plasma oral glucose tolerance test, the range is ≥ 11.1 
mmol/L (200mg/dL) [18]. An A1C test can also be performed using a standardized method to the 
Diabetes Control and Complications Trial (DCCT) with A1C criteria of ≥ 48 mmol/mol (6.5%) [18]. 
 
The clinical diagnosis of diabetes is associated with symptoms such as recurrent infections, weight 
loss, increased thirst, and urine volume. Severe symptoms include elevated levels of glycosuria, 
drowsiness eventually resulting in a coma [13, 15]. There are many forms of diabetes; these forms 
will be discussed next. 
 
1.2.1 Type one diabetes  
 
Type one is associated with processes of beta-cell destruction, which could eventually result in 
diabetes mellitus, whereby insulin would be required to prevent the onset of a coma and eventually 
resulting in death [15, 19-21]. It should be noted that type one diabetes is generally associated with 
the presence of islet cell antibodies, which result in the initiation of autoimmune responses, which 
eventually destroys the pancreatic beta cells [2, 15, 21]. 
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Autoimmune diabetes mellitus was previously referred to as juvenile-onset diabetes, type one 
diabetes, or insulin-dependent diabetes. This form of diabetes is a result of autoimmune-mediated 
destruction of the beta cells located in the pancreas. The beta cells' destruction is variable, ranging 
from slow in certain individuals to rapid in others [22]. The highest occurrence of this type of diabetes 
takes place at the onset of adolescence or during childhood; however, the onset of diabetes can occur 
at any age [23]. This form of diabetes is associated with an individual’s genetic predisposition to the 
autoimmune destruction of beta cells as well as environmental factors surrounding the individual, 
which is still poorly defined [15]. 
 
It must be noted that a few forms of one diabetes mellitus have no identifiable aetiology; this form of 
diabetes is classified as idiopathic diabetes. These patients have insulinopenia [15, 21] as well as a 
susceptibility to ketoacidosis [13]; however, there was no evidence of autoimmunity [24]. 
 
1.2.2. Type two diabetes  
 
Type two diabetes is associated with disorders of insulin secretion and action [2, 5, 13, 14]. Type two 
diabetes mellitus is rapidly increasing and is common due to the increase in the prevalence of obesity 
and a sedentary lifestyle [25]. 
 
The majority of patients suffering from type two diabetes are generally obese. Obesity exacerbates 
insulin resistance [26]. Contrary to this, several people are not obese according to conventional weight 
criteria and could have a higher amount of body fat mainly situated in the central abdominal region 
[27]. The likelihood of developing type two diabetes increases with the following risk factors; age, 
obesity, and reduced physical activity [28]. 
 
1.2.3 Gestational diabetes 
 
Gestational diabetes is characterized by carbohydrate intolerance; the onset or initial recognition is 
usually during pregnancy in certain individuals [15, 29-31]. Adult women, with a history of glucose 
intolerance, or high blood glucose levels are at a higher risk for developing gestational diabetes [15]. 
 
1.2.4 Genetic defects of beta-cell function and insulin action  
Monogenic defects in the beta-cell function are associated with numerous forms of diabetes, usually 
characterized by an early onset of mild hyperglycaemia presenting in patients before the age of 
twenty-five years. Patients presenting with the above form of diabetes were previously referred to as 
maturity-onset diabetes of the young (MODY). These patients display reduced secretion of insulin 
with negligible insulin action [32, 33]. 
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The abnormalities at three genetic loci were characterized, which were located on different 
chromosomes. The most common mutation is related to mutations located on chromosome twelve in 
the hepatic nuclear transcription factor known as HNF1a [34]. The second mutation is associated with 
the glucokinase gene located on chromosome 7p [35, 36]. Glucokinase plays an essential role in the 
conversion of glucose-6-phosphate, whereby the metabolism pathway, in turn, stimulates the secretion 
of insulin by the beta cells. Therefore, glucokinase functions as a glucose sensor for the beta cells. 
Due to the defective glucokinase gene, higher levels of glucose are required to mediate normal levels 
of insulin secretion. 
 
The third type of mutation is associated with a mutation in HNF4a located on chromosome 20q [32]. 
The transcription factor HNF4a is associated with gene regulation and expression of HNF1a. The 
fourth form is associated with mutations in a transcription factor gene Insulin promotor factor-1 (IPF-
1), in its homozygous form results in pancreatic agenesis [33]. Point mutations that occur in 
mitochondrial DNA were associated with deafness and diabetes mellitus [34]. A common mutation 
takes place in the transfer ribonucleic acid (tRNA) leucine gene at position 3243, resulting in an 
adenine to guanine substitution. Genetic defects that result in the failure to convert proinsulin to 
insulin are inherited in an autosomal dominant pattern with mild carbohydrate intolerance [37, 38]. 
 
Concerning genetic defects in insulin action, it must be noted that there are a few rare types of 
diabetes that occur from genetic anomalies of insulin action. These metabolic anomalies are linked 
with mutations of the insulin receptor can range from hyperinsulinemia to mild hyperglycaemia [37, 
39]. This metabolic syndrome was referred to as Type A insulin resistance [39]. Rabson-Mendenhall 
and Leprechaunism syndrome are paediatric syndromes that have mutations in the insulin receptor 
gene, consequently leading to changes in the insulin receptor function and severe insulin resistance 
[37]. 
 
1.2.5 Diseases of the exocrine pancreas and endocrinopathies  
 
Processes that injure the human pancreas can lead to diabetes mellitus; these processes include 
pancreatic carcinoma, pancreatitis, pancreatectomy, trauma, and infection [40]. The damage of the 
pancreas should be extensive for diabetes to occur, with cancer being an exception to this rule. For 
example, adenocarcinoma is located in the pancreas and was associated with diabetes [41]. Severe 
hemochromatosis can also damage beta cells, thereby impairing the secretion of insulin [42, 43].  
Endocrinopathies can also be associated with diabetes. Numerous hormones, such as cortisol, 
glucagon, growth hormone, and epinephrine, inhibit insulin action. Diseases such as Cushing’s 
syndrome, acromegaly, glucagonoma, and phaeochromocytoma are linked to excess secretion of these 
hormones, as a result, could cause diabetes [40, 44]. 
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1.2.6 Drug-induced and infections that cause diabetes 
 
Numerous drugs impede the secretion of insulin. Therapeutic drugs might not result in diabetes; 
however, these drugs can cause diabetes in patients with insulin resistance [45, 46]. Some toxins such 
as pentamidine [40, 47] and Vacor [40] can cause the destruction of pancreatic beta cells [40]. These 
drug reactions are rare. Numerous hormones and drugs can inhibit insulin action, such as 
glucocorticoids and nicotinic acid [45, 46]. 
 
Infections that cause diabetes can be associated with certain viruses and diseases which were linked 
with the destruction of beta-cells. Some patients with congenital rubella develop diabetes [47]. 
Cytomegalovirus, adenovirus, and mumps have also been identified in the induction of diabetes 
mellitus [48-50].  
 
Diabetes mellitus is also associated with a variety of immunological diseases with differing aetiology 
presented in type one diabetes patients. An autoimmune disorder of the central nervous system that is 
associated with painful spasms and stiffness of the axial muscles is referred to as stiff-man syndrome 
[51]. People who have this disorder generally have high titres of GAD autoantibodies, and about 
approximately half will eventually develop diabetes.  
 
1.2.7  Genetic and metabolic syndromes associated with diabetes  
 
Numerous genetic syndromes such as Turner’s syndrome, Down’s syndrome, Wolfram’s syndrome, 
and Klinefelter’s syndrome are associated with an increased risk of diabetes mellitus [52]. Other 
manifestations associated with diabetes include hypogonadism, neural deafness, diabetes insipidus, 
and optic atrophy. 
 
A person with diabetes suffers from irregular glucose tolerance and will generally also have one or 
more cardiovascular disease risk factors [16, 17, 53]. The symptoms of metabolic syndrome are 
present in patients up to ten years prior to the detection of glycaemic disorders [54]. This is a vital 
feature regarding the aetiology of cardiovascular disease risk and hyperglycaemia and the possible 
prevention of cardiovascular disease and mortality/morbidity in people with glucose intolerance [2, 
54]. Metabolic syndrome patients with normal glucose tolerance are at high risk for future diabetes. 
Early detection and management of this syndrome will have an imperative influence on the prevention 
of cardiovascular disease and diabetes. Metabolic syndrome is associated with impaired glucose 
tolerance, diabetes mellitus, glucose intolerance, or insulin resistance coupled with insulin resistance, 
raised arterial pressure and diabetes [54]. Regardless of the prevention of diabetes and metabolic 
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syndrome, the affordability of readily available human insulin is imperative in the treatment of 
diabetes and its associated diseases. 
 
1.3 The structure of insulin  
 
In 1921, insulin was discovered by Charles Best and Frederick Banting [55]. Insulin plays an essential 
role in glucose homeostasis [56]. Therefore, it is instrumental in the treatment of diabetes. It is a 51 
amino acid (aa) polypeptide. Insulin contains two polypeptide chains, the A chain has 21 amino acids. 
The B chain contains 30 amino acids. Insulin has three disulphide bonds. Two of the disulphide bonds 
interlink the A and B chains, whereas the third one is an intra A chain bond [56-61]. 
 
 
Figure 1: Insulin structure depicting polypeptide chains A and B, the A chain is depicted in brown, 
the B chain is depicted in blue, and the disulphide bonds are depicted in green, adapted from [59] 
(open access). 
 
The insulin molecules net charge is produced from the ionisation of four tyrosine residues, two 
histidine residues, four glutamic acid residues, an arginine residue, a lysine residue, two α-amino, and 
two α-carboxyl groups. Insulin is negatively charged at neutral pH and has an isoelectric point (pI) of 
5.3 in its denatured state [62]. Another intrinsic property of insulin is its innate ability to readily 
associate into higher-order states and dimers (Figure 2) [63]. The insulin molecule can associate into 
hexameric complexes in the presence of numerous divalent metal ions, for example, zinc [64]. X-ray 
crystallographic has identified the positions of six phenolic ligand binding sites on an insulin hexamer 
[65]. The ligand-binding stabilizes a conformational change that takes place at the N-terminal of the 
B-chain of insulin, shifting this conformational equilibrium of residues from B1 to B8 from a T-state 
to an R-state. This conformation transition is known as the T<−>R transition (Figure 2) [66].  
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Figure 2: (A) An illustration of a T-state monomer of insulin with secondary and tertiary structures, 
B1-B8 region in an extended conformation. The A-chain is depicted in grey, and the B-chain is blue. 
(B) An illustration of a T-state dimer of insulin with secondary and tertiary structures. The A-chain is 
depicted in grey, and the B-chain is blue and cyan. (C) An illustration of secondary and tertiary 
structures of insulin in a T-state hexamer. The A-chain is depicted in grey, and the B-chain is blue and 
cyan with zinc depicted in green. (D) A representation of secondary and tertiary structures of insulin 
as an R-state hexamer in the presence of preservative. The A-chain is depicted in grey, and the B-
chain is blue and cyan with zinc depicted in green, and the preservative is represented in magenta, 
picture adapted from [60]. 
 
1.4  Methods of verifying the biological activity of insulin  
 
Human insulin is essentially in the regulation of glucose uptake into muscle and fat cells [58, 67]. 
Insulin activates the protein receptor (tyrosine kinase), ion transport systems, and activates the 
stimulation of glucose within seconds or minutes [58, 67]. 
 
There are numerous in vitro and in vivo tests that are used to determine the biological activity of 
human insulin. The bio-potency of biosynthesised insulin was tested in vivo using a United States 
Pharmacopeia (USP) rabbit hypoglycaemia assay [68-70]. The in vitro assays comprise of 
radioimmunoassay’s (RIA) such as insulin receptor assays [67, 69-72]. In the radioimmunoassay, 
insulin can be radio-iodinated (
125
I insulin), and the insulin receptor is purified from 3T3-L1 
adipocytes [73]. The biological activity of insulin can also be assessed with insulin receptors derived 
from human lymphocytes and by measuring the lipid metabolism in rat hepatocytes and adipocytes 
[74]. Another in vitro test monitored the hexose uptake in 3T3-Ll adipocytes [73]. In this study, we 
determined the biological activity of biosynthesised human insulin using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide) MTT assay using the Hepatocellular carcinoma (HepG2) cells.  
 
 
 
 
 
A B C D
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1.5  Polymerase chain reaction (PCR)  
 
The polymerase chain reaction is a molecular technique used for mass amplification of DNA [75, 76]. 
PCR is an in vitro enzymatic technique which is used for the synthesis of DNA; two oligonucleotide 
primers hybridize the opposite strands of the target DNA [77, 78]. PCR was developed by the scientist 
Kary Mullis in 1984 [76, 79]. The PCR reaction requires three main components, such as a 
polymerase, template of DNA as well as the building blocks of DNA the nucleotide bases such as 
guanine, adenine, thymine, and cytosine [77]. 
 
It is an exponential amplification process that comprised of three steps: extension, annealing, and 
elongation [75, 77, 80, 81]. During the denaturation step, the DNA is exposed to high temperatures 
such as 90 °C to 97 °C and denatured. In the annealing step, the primers anneal to the DNA target 
strands. In the extension step, an extension of the DNA occurs, creating a complimentary copy strand 
of nucleic acid [75, 80]. 
 
PCR is a rapid confirmatory test that is highly specific and sensitive [75, 80]. PCR has a vast array of 
applications and is used in many fields of science, such as molecular biology and microbiology for 
DNA sequencing, cloning, and recombinant DNA technology [75, 81]. It’s also used in forensic labs 
to amplify DNA from hair and blood samples, where a small amount of original DNA was available 
[75]. This study used PCR to clone human insulin and verify the positive transformants using colony 
PCR. 
 
1.6 The biosynthesis of insulin using recombinant DNA technology 
 
The first report of the synthesis of insulin by recombinant DNA technology was in 1978 by Goeddel 
and co-workers [82, 83]. In the initial biosynthesis of insulin, the A and B chains were combined and 
expressed separately in E. coli, yielding approximately 20 nanograms (ng) of insulin, which was 
detected by radioimmunoassay [70, 83]. This novel breakthrough in science started a major shift in 
insulin production, from the traditional animal pancreatic derived insulin to recombinant biosynthesis 
of insulin [70, 83, 84]. 
 
The use of recombinant technology is imperative for the production of recombinant proteins utilised 
for the development of protein drugs. Furthermore, recombinant protein production has an essential 
role in drug development. Recombinant proteins are produced in bacterial hosts, accounting for an 
estimated thirty percent of the current biopharmaceuticals in the market [85]. 
 
 
10 
 
In 1978, the gene encoding for human insulin was cloned and expressed in E. coli. Thereafter in 1982, 
Genentech developed human insulin, which was licensed and marketed by Eli Lilly [8, 61, 70, 84]. 
This was the first licensed drug produced using recombinant DNA technology [8]. 
 
Initially, recombinant human insulin was produced by the separate expression of insulin A and B 
chains in E. coli [61, 68-70, 83]. After purification of these two chains were incubated under 
oxidizing conditions. This promoted the formation of intact insulin by disulphide bond formation 
resulting in mature insulin [69, 83]. Subsequently, an alternate expression method was developed in 
E. coli utilising the nucleotide sequence encoding for human proinsulin. Purification of proinsulin was 
followed by in vitro proteolytic excision of the connecting C peptide, resulted in mature insulin [61, 
68, 70, 83]. This method was more efficient for the large scale synthesis of insulin as compared to the 
two chain combination approach and has been used commercially since 1986 [83]. 
 
1.7 The use of affinity tags in protein purification 
 
Approximately 30% of therapeutic proteins are biosynthesised in E. coli using recombinant 
technology. There is comprehensive knowledge available regarding the fermentation profile of E. coli, 
expression vectors, strains, and protein folding [8, 86, 87]. E.coli has the following positive attributes 
such as its genetics are well characterized, displays rapid growth, and has a high production yield of 
proteins, easy to handle, and it is amenable to numerous genetic modifications thereby making it an 
ideal expression host [8, 86, 88, 89]. E. coli is an ideal bacterial expression host for large scale 
production of therapeutic proteins [87, 90-94]. The expression of a therapeutic protein requires a 
multidisciplinary approach [90]. There have been advances made with regards to protein refolding 
from inclusion bodies, molecular biology, and fermentation utilising E. coli. However, some 
bottlenecks that impact the cost-effectiveness of the biosynthesis of therapeutic proteins, such as the 
purification of therapeutic proteins from inclusion bodies, which result in low yields of the bioactive 
protein [90, 95]. 
 
Affinity tags are referred to as exogenous amino acid sequences that have a high affinity for a 
particular chemical or biological ligand. These tags are efficient tools for protein purification. The 
protein of interest and the tag are expressed as a single entity and subsequently purified. The tag has 
to be removed from the target protein as it can affect the physiochemical characteristics of the protein 
[96]. The cost incurred in the tag removal prevents large scale industrial applications [96, 97]. Due to 
advances in cutting edge technology in bioinformatics, proteomics, and genomics, the number of 
recombinant proteins is increasing rapidly [98]. Consequently, high throughput screening methods are 
required to rapidly identify the potential proteins with therapeutic or industrial enzymes [99].  
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Affinity tags have an essential role in protein purification. Affinity chromatography can achieve 90-
99% purity. The use of affinity chromatography saves time due to the reduction in the number of 
chromatographic steps. As such, affinity tag technology will increase high-throughput purification, 
drug delivery methods, and large scale production plants [100]. There are a variety of affinity tags; 
this study employed histidine and glutathione S-transferase tags.  
 
Immobilized metal affinity chromatography (IMAC) is extensively used to purify recombinant 
proteins with a small affinity tag comprising of poly-histidine residues. IMAC is based on the 
interaction with the specific amino acid side chains and a transition metal ion (such as a Zinc ion 
(Zn
2+
), Copper ion (Cu
2+
), Nickel ion (Ni
2+
), Cobalt ion (Co
2+
))  immobilized in a matrix [101]. The 
histidine amino acid exhibits the strongest interaction between the immobilized metal ions in the 
matrix. The electron donor groups located in the histidine imidazole ring form coordination bonds 
with the immobilized transition metal. Peptides that contain consecutive histidine residues are retained 
on the IMAC column matrix. After washing the matrix, the peptides which contain poly-histidine 
sequences are eluted by adding free imidazole or by adjusting the pH of the column buffer [100]. The 
poly-histidine affinity tag, also referred to as His six or His-tag, contains six consecutive histidine 
residues, however, can differ in size from two to approximately ten histidine residues [102]. 
 
Histidine tags are one of the most commonly used affinity tags. The purification is based on the use of 
chelated metal ions as affinity ligands. IMAC protein separation occurs based on the interaction 
between metal ions contained in an immobilized metal matrix and particular amino acid residues such 
as histidine [103]. The imidazole group of histidine has a high affinity for chelated metals [66]. The 
use of histidine tags at the carboxyl (C) or amino (N) terminals aids in the protein purification of the 
recombinant protein from the crude extract of the expression host in one step. There are a variety of 
strategies available for IMAC [103, 104], the most prevalent IMAC supports different chelating 
sepharose matrices or either nitrilotriacetic acid (NTA) as a ligand for immobilizing metals such as 
nickel (Ni–NTA). The binding specificity allows the purification of proteins under denaturing and 
native conditions [103]. The histidine tag is cleaved by a cleavage enzyme such as Tobacco Etch 
Virus (TEV) protease [105].  
 
The pGex (Glutathione S-transferase) GST fusion protein system is used for the high-level 
purification of fusion proteins from bacterial and eukaryotic cell lysates [106]. In 1988 the single-step 
purification of polypeptides as fusions with GST was described [107]. These fusion proteins can be 
purified from the crude lysate by utilising affinity chromatography on immobilized glutathione 
matrices. Furthermore, the bound fusion proteins are eluted with reduced glutathione (10 mM) in non-
denaturing conditions. The affinity tag can assist in the protection against intracellular protease 
cleavage and thereby, stabilize the cloned protein of interest [106].  
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The GST tag can be cleaved from the fusion protein while still attached to glutathione agarose, 
thereby providing a convenient method for the separation of the 26 kDa (kilo-dalton) GST tag from 
the protein of interest [102]. 
 
The removal of the affinity tag must be taken into consideration, and these proteases must be removed 
from the purified protein if the protein is intended for human use. Affinity tags can affect the 
functions and characteristics of the recombinant protein. Therefore the removal of the affinity tag 
from the protein may be achieved by the use of site-specific proteases [100]. Enterokinase is generally 
used for N-terminal fusions as it recognizes a five amino-acid polypeptide and cleaves the carboxyl 
end of lysine (D-D-D-D-K-X1) [100]. 
 
1.8 Traditional methods for insulin purification  
 
Chromatography is an imperative separation method that allows for quantitative and qualitative 
analysis separation, identification, and purification of individual components of a mixture [108]. 
Biologics such as insulin are currently purified using reversed-phase high-performance liquid 
chromatography (RP-HPLC) [84].  
 
The strategies of insulin biosynthesis in yeast and E. coli contain enzymatic and chemical reactions in 
the downstream processes. Thus, resulting in the formation of numerous derivatives associated with 
insulin, which is tedious to remove by conventional purification. Novo Nordisk A/S and other 
companies utilised RP-HPLC for protein purification [68]. The characteristics of a protein have a 
fundamental role in its purification, such as the total charge of a protein, hydrophobic groups 
displayed on the protein surface, the binding capacity of the protein to a stationary phase, shape, and 
size [108]. 
 
Samples can be separated by various forms of chromatography, such as affinity, ion exchange, and 
size exclusion chromatography (SEC) [109]. HPLC is a chromatographic separation technique that is 
extensively used for the quantitative separation and purification of steroids, amino acids, proteins, 
antibiotics, vitamins, hydrocarbons, nucleic acids, carbohydrates, polysaccharides and drugs [108, 
109]. HPLC system was comprised of an injector, pumps, columns, detectors, and a data system. The 
sample is injected into the system by an injector, allowing the placement of the sample into the mobile 
phase, thereafter it is transported to the column. The pump transports the mobile phase throughout the 
system. The column comprises of a polymer or stainless-steel hardware that is filled with a specific 
separation packing material. Numerous packing materials comprise of polymeric such as 
microporous, mesoporous, macro-porous and nonporous or silica based such as bonded phases, or 
porous silica. The success of silica-based separation has led to numerous applications in reverse and 
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normal phase HPLC separation. After the sample is passed to the column, it is detected by a detector, 
the detectors used in HPLC can include light scattering, fluorescence, electrochemical, and ultraviolet 
(UV)-Vis absorption. Analytical systems can also be coupled to mass spectrometers [109]. A 
schematic representation of an HPLC is illustrated in Figure 3. HPLC is highly versatile and has 
analytical precision. There are numerous advantages over low-pressure liquid chromatography, such 
as better resolution, higher sensitivity, speed, the availability of a multitude of stationary phases, and 
easy sample recovery [109]. 
 
 
Figure 3: A schematic diagram of an HPLC system [110] (open access). 
 
HPLC is the conventional method employed for the purification of biologics such as insulin [61, 68, 
84]; however, this study will employ a greener form of SFC purification, which will be discussed 
next. 
 
1.9  SFC purification  
 
SFC is a purification technique that utilises a supercritical fluid as a mobile phase. This supercritical 
fluid is a condensed gas, such as carbon dioxide (CO2) [111-114]. The aforementioned fluid is 
generally above the critical pressure and temperature [111-113]. CO2 reaches its supercritical fluid 
state at a pressure of 73 bar and a temperature of 31°C [111-113]. A CO2 phase diagram is illustrated 
in Figure 4.  
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Figure 4: CO2 phase diagram adapted from [115]. 
 
In an SFC system, the mobile phase is transported at a cold temperature such as 4°C to the pump and 
heated in the column oven above the supercritical temperature [116]. A back pressure regulator is 
used to maintain critical pressure throughout the SFC system [111, 117]. The sample is injected into 
the SFC system via an injector. The supercritical fluid carries the sample through a separation column. 
The sample is detected using a UV detector [111]. In order to improve the elution of organic 
substances, modifiers can be added [111]. Subsequently, the CO2 is separated from the modifier and 
the eluted compounds via the expansion in the gas and liquid separators. The majority of the separated 
CO2 leaves the system through an exhaust pipe and sent to a ventilation system. Thereafter, the 
fractions are collected; these fractions contain residual CO2 and the separated compound [111, 113]. A 
schematic representation of the SFC is illustrated in Figure 5. 
 
Figure 5: A schematic representation of a typical SFC flow path [118] (open access). 
 
 
 
  Temperature (°C) 
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The SFC kinetics and thermodynamics provides a faster separation method than HPLC. SFC has the 
following advantages over HPLC, such as higher efficiency separation of drug substances and 
intermediates, short analysis time, faster method development, stacked injections, and column 
equilibration [112, 113, 117, 119-121]. There is a reduction of toxic and hazardous waste generated 
from SFC purification; as a result, it is a greener process [112, 113, 117]. The reduction in toxic 
solvent waste has health, safety, and cost benefits [112, 113]. The high-speed throughput of SFC 
purification is being used rapidly for semi-preparative and preparative as well as analytical 
purification of chiral compounds, which is extensively used in drug development [112, 113, 117]. 
Another advantage of SFC is the ease of recycling an unresolved fraction when the overlapping of 
chromatogram peaks occurs and poor peak resolution [117]. SFC can be utilised as an alternative 
purification method to HPLC for drug substances; as such, SFC is replacing HPLC in several 
pharmaceutical industries, such as purification, screening, and method development for chiral 
compounds such as enantiomers [112, 113, 117, 121]. HPLC uses toxic solvents such as acetonitrile. 
This study aims to use methanol as a green solvent to provide a novel method of purifying human 
insulin and other biologics. SFC is considered to be an environmentally friendly technology; it 
eliminates the use of hexane, heptane and acetonitrile, which is used in HPLC [113, 117]. As far as 
we are aware, this is one of the first studies to purify biosynthesised human insulin using SFC. 
 
1.10  Purification of peptides  
 
Peptides are used in the pharmaceutical industry and are highly versatile drugs as they can be 
employed for the treatment of type two diabetes [122]. Peptides display numerous advantages as 
drugs such as low toxicity, high biological activity, and high specificity [122, 123]. Peptides can be 
antimicrobial, antibacterial, anti-cancer, and anti-viral [122, 124, 125]. Peptides are used in various 
therapeutic fields, such as diabetes, arthritis, allergy, oncology, cardiovascular, and diagnostic 
research [123, 126]. 
 
There are numerous challenges associated with developing peptide drugs such as stability, solubility; 
however, the major hurdle associated with the peptide manufacturing process is peptide purification 
[123]. The downstream processes are very expensive due to yield losses experienced during HPLC 
purification, which is another major bottleneck experienced during the peptide manufacturing process 
[123, 125]. Therefore, extensive research should be conducted in the process of the development of 
peptide drugs to save time and costs [123]. Therefore, this study aims to purify peptides using SFC 
purification. 
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1.11  Matrix-assisted laser desorption ionisation-time of flight mass spectrometry  
 
Matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF-MS) is an 
inexpensive method used for the rapid detection of fungal and bacterial organisms [127-137]. Mass 
spectrometry is an analytical method that is semi-quantitative and used for the elucidation of 
molecular structure or the composition of unidentified samples [127]. MALDI-TOF-MS is considered 
a soft ionisation technique because it ionizes biomolecules without causing fragmentation that is 
normally associated with traditional ionisation methods. The lack of fragmentation of small analytes 
allows for the identification of specific analytes against a backdrop of other signals; therefore, the 
presence of metabolites and small drugs can be identified from a range of other biomolecules [138]. 
 
Instruments that are used in mass spectrometry are comprised of three components an ionisation 
chamber, followed by a mass analyser and a detector (Figure. 6) [127]. In MALDI-TOF-MS a target 
plate is initially placed under vacuum, and a co-crystallized mixture of matrix and analyte is irradiated 
by a laser beam, resulting in localized heating of the analyte followed by desorption and ionisation, an 
ionic plume of ions are accelerated into the mass analyser by electric fields, thereafter the mass of the 
analyte is detected [138]. The matrix is used in MALDI to protect molecules from thermal 
degradation after irradiation by a pulsed laser, as the photons are absorbed by the matrix and 
thereafter transferred to the analyte in a relatively controlled manner [139] (Figure 6). 
 
 
Figure 6: MALDI-TOF-MS sample ionisation process [140]. 
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There are numerous advantages in the use of MALDI-TOF-MS, such as it does not require 
chromatographic separation, easy to use, fast detection of a variety of samples, and relatively simple 
sample preparation [129, 130, 141, 142]. A disadvantage of MALDI-TOF-MS is that it is less 
quantitative due to the efficiency of ionisation as a result of the heterogeneous distribution of the 
analyte and matrix co-crystallization [141, 142]. Other disadvantages include variability in signal 
intensity and poor reproducibility [142]. The shot to shot reproducibility is affected by the depth of 
the crystal layer, crystal sizes, and the distribution of the analyte throughout the crystallized matrix 
and analyte mixture [143]. This study employed MALDI-TOF-MS to detect biosynthesised human 
insulin. 
 
1.12  Protein sequencing  
 
Mass spectrometry has become an imperative tool for the determination and elucidation of amino acid 
sequences of peptides and proteins [144]. There are soft ionisation techniques such as MALDI [145] 
and electrospray ionisation [146], which are used to produce intact protein and peptide ions with 
minimal fragmentation located in the gas phase. There are more fragment ions detected in the above 
ionisation techniques compared to chemical ionisation and electron impact mass spectrometry [147]. 
These ions are rapidly detected with their mass to charge (m/z) ratios allowing for quick validation of 
peptides and proteins, which also allows for peptide mass fingerprinting [148-150]. Mass 
spectrometry is extensively used for the determination of peptides structure due to the different 
ionisation techniques available [147]. 
 
Peptide mass fingerprinting is based on the digestion of a protein or peptide by an enzyme such as 
trypsin; thereafter, the peptides are analysed using reverse-phase chromatography [144, 151]. The 
peptides are ionized and fragmented to form a signature from tandem mass spectrometry (MS/MS) 
spectra, which are used for rapid identification [151]. The peptides are identified by comparing the 
generated MS/MS spectra against the peptide sequences in peptide databases such as Mascot and 
SEQUEST [144, 152-154]. 
 
The peptide fragmentation pattern is dependent on numerous factors such as the charge of the ion, the 
size of the peptide, the amino acid composition, and the excitation method employed [144]. The 
peptide precursor ions dissociate under low collision energy parameters, which fragment the peptide 
backbone at the amide bonds [155-157]. There are three potential cleavage points in a peptide 
backbone A, B and C if there is a charge retained at the N-terminal of the peptide and if the charge is 
retained at the C terminal of a peptide then it is given the nomenclature of X, Y, and Z [147]. 
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1.13  Aims and objectives of the study  
 
1.13.1 To develop a novel and more efficient method for human insulin biosynthesis using 
recombinant DNA technology in E. coli (Chapter 2). 
1.13.1.1 To verify human insulin using chromosomal DNA via PCR.  
1.13.1.2 To detect and identify biosynthesised human insulin using MALDI-TOF-MS.  
1.13.1.3 To conduct Liquid Chromatography-Mass Spectrometry (LC-MS) on the standard human 
insulin and biosynthesised human insulin samples. 
1.13.1.4 To conduct protein sequencing of standard human insulin and biosynthesised human insulin. 
1.13.1.5 To determine the biological activity of the standard human insulin and the crude 
biosynthesised human insulin using an in vitro MTT assay. 
1.13.1.6 To conduct LC-MS of the standard human insulin and biosynthesised SFC purified human 
insulin samples. 
1.13.2  Can human insulin be purified using SFC? (Chapter 3). 
1.13.2.1 To purify human insulin using SFC. 
1.13.2.2 To conduct protein sequencing of human insulin after SFC purification. 
1.13.2.3 To determine the biological activities of standard human insulin and biosynthesised human 
insulin using an in vitro MTT assay. 
1.13.3. Can crude peptides such as a tetrapeptide, octapeptide and a nonapeptide be purified using 
SFC? (Chapter 4). 
1.13.3.1 To determine if a tetrapeptide, octapeptide, and a nonapeptide are soluble in methanol. 
1.13.3.2 To develop an SFC purification method for a crude tetrapeptide, octapeptide and a 
nonapeptide. 
1.13.3.3 To conduct LC-MS on the SFC purified tetrapeptide, octapeptide and nonapeptide. 
 
1.14  Outline of thesis 
 
This dissertation is divided into five chapters, including Chapter one. 
Chapter one provides an overview of the current understanding of diabetes and the characteristics of 
insulin biosynthesis and purification.  
Chapter two contains research data pertaining to the biosynthesis and optimisation of human insulin 
expression in E. coli. 
Chapter three comprises of research data pertaining to the SFC purification of human insulin. 
Chapter four pertains to research data regarding the SFC purification of peptides. 
Lastly, Chapter five describes conclusions drawn from this study and reflects on future research 
endeavours. 
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Abstract 
 
Insulin has captured researchers’ attention worldwide. There is a rapid global rise in the number of 
diabetic patients, which increases the demand for insulin. Current methods of insulin production are 
expensive and time-consuming. A PCR-based strategy was employed for the cloning and verification 
of human insulin. The human insulin protein was then overexpressed in E. coli on a laboratory scale. 
Thereafter, the optimisation of human insulin expression was conducted. The yield of human insulin 
produced was approximately 520.92 (mg/L), located in the intracellular fraction. Human insulin was 
detected using MALDI-TOF-MS and LC-MS methods. The crude biosynthesised protein sequence 
was verified using protein sequencing, which had a 100% similarity to the human insulin sequence. 
The biological activity of human insulin was tested in vitro using a MTT assay, which revealed that 
the crude biosynthesised human insulin displayed a similar degree of efficacy to the standard human 
insulin. This study eliminated the use of affinity tags since an untagged pET21b expression vector 
was employed. Tedious protein renaturation, inclusion body recovery steps, and the expensive 
enzymatic cleavage of the C-peptide of insulin were eliminated, thereby making this method of 
biosynthesising human insulin a novel and more efficient method.  
 
Keywords: 
biosynthesis of human insulin; diabetes; E. coli.  
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1 Introduction  
 
In 2018, it was estimated that 405.6 million people suffered from Type 2 diabetes, and this number is 
projected to increase to approximately 510.8 million by the year 2030. Based on these estimates, the 
global usage of insulin is estimated to rise from 516.1 million vials (1000 IU) to 633.7 million vials in 
2030 (Basu et al., 2019). The increase in diabetic patients, coupled with the development of oral and 
inhalation methods of insulin delivery, requires considerable amounts of insulin. The current 
producers of insulin would not be able to cope with the rapid demand of affordable insulin as a result 
of high production costs and production capacity limitations (Baeshen et al., 2014). 
 
Insulin has an essential role in glucose homeostasis (Ahmad 2004). It is produced by the beta cells of 
the pancreas and is one of the main anabolic hormones in the human body (Voet and Voet, 2011). It is 
synthesised by beta cells in the pancreas and has a fundamental role in fat and carbohydrate 
metabolism (Ahmad, 2004). Human insulin is a 51 amino acid (aa) polypeptide. It contains two 
polypeptide chains. The A chain has 21 amino acids and the B chain contains 30 amino acids. Insulin 
has three disulphide bonds. Two of the disulphide bonds interlink the A and B chains, whereas the 
third one is an intra A chain bond (Ahmad, 2004; Vajo et al., 2001). Insulin was first discovered in 
1921 by Charles Best and Frederick Banting (Banting & Best, 1922). Prior to 1982, insulin was 
extracted from the pancreas of animals such as bovines and porcine (Beals et al., 2013; Mollerup et 
al., 2009).  
 
The biotechnological industry can, possibly, develop suitable innovations to curb the shortage in the 
supply of human insulin. Novel innovations in methods of insulin production and purification have 
the potential to significantly advance the pharmaceutical biotechnology industry. The use of 
recombinant deoxyribonucleic acid (DNA) technology allowed for a direct method of biosynthesising 
human insulin, which did not require animal-derived pancreatic tissue (Walsh, 2005). In 1982, Novo 
Nordisk derived semi-synthetic human insulin, whereby porcine insulin was converted into human 
insulin enzymatically. Human insulin was biosynthesised by Eli Lilly using recombinant DNA 
technology in 1982. Two production methods were reported by Eli Lilly (Mollerup et al., 2009). The 
first method consisted of cloning the A and B chains of insulin separately in E. coli; thereafter, these 
two chains were isolated, purified, and chemically attached. Subsequently, the final reversed phase-
high performance liquid chromatography (RP-HPLC) purification steps were conducted (Chance et 
al., 1981; Frank & Chance, 1983; Mollerup et al., 2009). The second method of cloning recombinant 
insulin in E. coli consisted of the expression of proinsulin under a tryptophan promoter that had a 
methionine bond to proinsulin. This study cloned the A and B chains of human insulin together in E. 
coli. In 1988 Novo Nordisk launched the biosynthesis of human insulin using recombinant DNA 
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technology (Mollerup et al., 2009). The proinsulin biosynthesis strategy of human insulin is the 
preferred method.  
 
However, this procedure results in the formation of inclusion bodies and requires the use of enzymes 
such as carboxypeptidase B to remove the C-peptide (Redwan et al., 2007; Zieliński et al., 2019) and 
the use of affinity tags (Redwan et al., 2007). The inclusion body formation requires additional steps 
to be taken, such as the renaturation of the protein (Redwan et al., 2007; Zieliński et al., 2019). This 
study aimed to create a novel and efficient method for the biosynthesis of human insulin employing a 
polymerase chain reaction (PCR)-based strategy using the pET21b expression vector in E. coli for the 
optimisation of human insulin expression.  
 
2 Materials and methods  
 
2.1 Bacterial strains  
 
The bacterial strains employed in this study were obtained from the School of Life Sciences, in the 
Discipline of Microbiology (University of KwaZulu-Natal, Westville Campus, South Africa). The 
pCMV6-XL5 plasmid integrated with the gene encoding for human proinsulin was procured from 
ORI Gene (United States of America (USA). Commercial human insulin protein was obtained from 
Sigma-Aldrich Inc (Germany) as a control in this study. All restriction enzymes were purchased from 
Thermo-Scientific, USA. 
 
2.2 Cloning of human insulin in E. coli 
 
An amplification of human insulin was conducted using a PCR master mix according to the 
manufacturer’s instructions (Thermo-Scientific, USA). The pCMV6-XL5 plasmid was used as a DNA 
template with the following primers: (PGEX-BamHI-F: 5’-GGA TCC ATG GCC CTG TGG ATG 
CG–3’ and PGEX-XhoI-R: 5’–CTC GAG CTA GTT GCA GTA GTT CTC C–3). The PCR 
conditions were as follows: a denaturation at 95°C for 30 seconds, followed by an annealing step at 
61.2°C for 30 seconds; thereafter an elongation step at 72°C for one minute, and lastly another 
elongation at 72°C for two minutes. The PCR comprised 30 cycles. The PCR amplicons were 
subsequently visualised on a 1.5% agarose gel (Helling et al., 1974) and viewed using a Syngene G 
BOX gel documentation system (Vacutec, South Africa). The respective band was cut off using a 
scalpel under a UV trans-illuminator (UVP incorporated, USA). PCR products were then purified 
using the Zymoclean™ gel DNA recovery kit (ZYMO Research, USA), following the manufacturer’s 
instructions.  
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The pET21b vector DNA was isolated using a Zyppy™kit (ZYMO Research, USA), as per the 
manufacturer’s instructions. Thereafter, the PCR amplicons and the pET21b vector were digested 
with BamHI and XhoI, according to the manufacturer’s instructions (Thermo-Scientific, USA). 
Thereafter, the restricted PCR products were inserted into the pET21b vector using T4 DNA ligase 
(Thermo-Scientific, USA), according to the manufacturer’s instructions. The pET21b vector human 
proinsulin (designated as pET21b-hPin) was transformed in chemically competent E. coli BL21 
(DE3) cells plasmid using the calcium chloride heat shock method (Inoue et al., 1990).  
 
2.3 The expression and isolation of the protein  
 
The transformed E. coli BL21 (DE3) (Thermo-Scientific, USA) was verified using colony PCR. The 
positive clones were incubated in 10 mL of Luria-Bertani (LB) medium (1% bacto tryptone, 0.5% 
yeast extract, 1% NaCl) containing 50 μg/mL ampicillin and 34 μg/mL chloramphenicol (Merck, 
Germany) overnight at 37°C at 180 revs per minute (rpm). One mL of an overnight culture was used 
to inoculate 100 mL of LB broth using the above method (Maseko et al., 2016; Volontè et al., 2011). 
The expression of human proinsulin was induced by the addition of 0.1 to 1 mM Isopropyl β-D 
thiogalactoside (IPTG) at an early exponential phase (OD600 0.4-0.7).  
 
The over-expressed protein was recovered following to a similar method adapted from Maseko et al. 
(2016). After overnight induction at 16°C, the cultures were transferred to 50 mL Cell Star® 
centrifuge tubes (Greiner Bio-One, Austria) and spun down at 8000 rpm for 15 minutes at 4°C. The 
pellet was resuspended in 50 mM Tris-HCl (pH = 8). The crude protein extracts were sonicated for 
five to ten minutes on ice until the cells were homogenised with a Sonic Ruptor 400 Ultrasonic 
homogeniser (Omni International, United States of America). Thereafter, the samples were 
centrifuged at 8000 rpm for approximately 15 minutes at 4°C, and the supernatant was transferred to a 
clean centrifuge tube and stored at 4°C. The proinsulin was converted to mature human insulin as a 
result of the autocatalytic cleavage of the C-peptide (Gooch, 2011). Thereafter, the crude protein was 
concentrated using 3 kDa (kilo-Dalton) Amicon
®
ultra-size exclusion centrifugal filters (Merck, 
Germany), according to the manufacturer’s instructions. 
 
2.4 Detection of human insulin by matrix-assisted laser desorption ionisation-time of 
flight-mass spectrometry (MALDI-TOF-MS)  
 
The auto flex III smart beam MALDI-TOF-MS (Bruker Daltonics, Germany) was used for the 
detection of the standard human insulin and biosynthesised human insulin samples. The MALDI-TOF 
spectra were obtained from linear mode, where by ions charged at a voltage of 20 kilovolts (kV) 
within a molecular mass detection range of 1500 to 7000 Daltons (Da) were employed.  
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The instrument contained an ultraviolet nitrogen laser at 337 nanometres (nm). FlexControl version 
3.4 build 119 software was used for the data acquisition and FlexAnalysis of the MALDI-TOF 
spectra. The target that was employed in the study was a ground steel target plate (Bruker Daltonics, 
Germany). The protein samples were diluted and spotted on the ground steel plate according to the 
manufacturer’s instructions (Bruker Daltonics, Germany). The matrix utilised in this study was alpha-
cyano-4-hydroxycinnamic acid (CHCA or HCCA) (Bruker Daltonics, Germany). A standard curve 
was generated whereby standard human insulin was diluted to the required concentration using the 
HCCA matrix. The standard curve comprised of 0 ng/mL, 10 ng/mL, 50 ng/mL, 100 ng/mL, and 1000 
ng/mL concentrations (Refer to Figure S4 in the supplementary section.). 
 
2.5 Liquid chromatography-mass spectrometry (LC-MS)  
 
The sample containing human insulin was further confirmed using the LC-MS-2020 (Shimadzu, 
Japan) with a YMC-Triart C18 column (150 mm x 4.6 mm internal diameter, the pore size of 120 Å 
and a particle size of 5 μm) (YMC, Japan), coupled to a NM32LA nitrogen generator (Peak Scientific 
Instruments, United Kingdom). The MS spectra were obtained using the positive mode with a mass 
range of 200 to 1500 m/z. Mobile phase A was Millipore water (Millipore, USA) and mobile phase B 
was acetonitrile (Merck, Germany). Both these mobile phases contained 0.1% (v/v) formic acid as an 
ion-pairing agent. Flow rates of 1.0 mL/minute were used with a total run time of 25 minutes. The 
gradient profile was from 5% to 95% acetonitrile in seven minutes; and at 95% acetonitrile for a 
further 18 minutes. The column temperature was maintained at 40°C. The nebuliser was set at 1.5 bar 
with a desolvation gas temperature of 250°C and dry gas flow rates of 10 L/minute. 
 
2.6 Protein sequencing of human insulin 
 
In-solution digestion of the protein samples were conducted at the Central Analytical Facility 
(Stellenbosch University, South Africa) on an Ultimate 3000 RSLC (Thermo Fisher Scientific, USA), 
coupling with a mass spectrometry (fusion mass spectrometer) (Thermo Fisher Scientific, USA) and 
an ionisation source (Nanospray Flex). The files generated from the mass spectrometer were imported 
onto the Proteome Discoverer v1.4. The procedure was conducted according to the manufacturer’s 
instructions (Thermo Fisher Scientific, USA), and analysed using an Amanda algorithm and Sequest. 
Thereafter, a concatenated database interrogation was conducted using the Uniprot P09211, 
concatenated with the contaminant protein database (cRAP). The peptides were validated using 
Target-Decoy PSM validator mode. The results were imported according to the manufacturer’s 
instructions using Scaffold 1.4.4 software (Proteome Software Inc, USA), and the identified peptides 
were validated with the peptide, Protein Prophet, as well as X!Tandem algorithms from the Scaffold 
1.4.4 software (Proteome Software Inc, USA). 
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2.7 Biological activity 
 
The biological activity of the standard human insulin and the crude biosynthesised human insulin was 
conducted in vitro using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) 
assay. Hepatocellular carcinoma (HepG2) (Highveld Biologicals, South Africa) cell line was used. 
The HepG2 cells were cultured according to a method similar to that reported by Abdul et al. (2016). 
The cell culture reagents were obtained from Whitehead Scientific (South Africa). The standard 
human insulin and crude biosynthesised human insulin stocks were made in Eagle's minimum 
essential medium (EMEM) (catalogue number: 12-136F, Lonza, Switzerland) up to a concentration of 
1 mg/mL. In the MTT assay, three treatment concentrations were used of the standard human insulin 
and crude biosynthesised human insulin: low (50 μg/mL), medium (100 μg/mL), and high (150 
μg/mL).  
 
The HepG2 cells were seeded into a 96-well plate (2x10
4 
cells/well, 24 hours). Thereafter, the culture 
medium was removed, and cells were washed with PBS. The HepG2 cells were then treated with 
standard human insulin and crude biosynthesised human insulin hyperglycaemic (25 mM) media 
(Chen et al. 2006) for 15 minutes. The treatments were removed by washing the cells in PBS, and 120 
µl MTT (5 mg/ml, PBS) was added to each well. This was followed by an incubation of four hours at 
37°C. The formazan crystals were solubilised by the addition of 100 µl/well DMSO. The optical 
densities (OD) were measured spectrophotometrically (BioTek uQuant, USA) at 570 nm with a 
reference wavelength of 690 nm. All experiments were conducted in triplicate. 
 
The following formula was used to calculate cell viability (%): 
 
% 𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑂𝐷 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑂𝐷 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠
× 100 
 
2.8 Statistical analysis 
 
Two-way analysis of variance (ANOVA) was conducted. Analyses were performed using the 
statistical software package Graph pad in stat version 8.1.0 (325) 64 bit for Windows (Graph pad 
software, San Diego California). 
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3 Results 
 
3.1 PCR amplification and purification of human proinsulin replicons 
 
PCR amplification of human proinsulin was conducted using PCR primers PGEX-BamHI-F and 
PGEX-XhoI-R. The mass amplified and purified product corresponded to the expected amplicon size 
of 345 bp (Figure S1a, lane 2). The human proinsulin replicons were inserted into pET21b. The 
pET21b-hPin plasmid (Figure 1) was then transformed successfully into E. coli BL21 (DE3) cells, 
which were confirmed by colony PCR (345 bp; Figure S1b).  
 
Figure 1: Images displaying the PCR amplicons of proinsulin DNA, purified vector DNA, and the 
integrated pET21b-hPin vector with the inserted proinsulin gene. Lanes 1 and 12 contain one kb 
molecular weight marker. Lanes 2 to 7 contain the PCR amplicons of proinsulin flanked with BamHI 
and XhoI restricted ends; Lane 8 contains the purified pET21b miniprep product; Lanes 9 to 11 
contain the integrated pET21b-hPin vector miniprep products. 
 
3.2 Detection and optimisation of expression of human insulin using MALDI-TOF-
MS  
 
The expression of human insulin was conducted by expressing the protein at varying IPTG 
concentrations, such as 0.1 mM, 0.5 mM, and 1 mM. The standard human insulin and the crude 
biosynthesised human insulin were detected using MALDI-TOF-MS, as the expected size of human 
insulin was obtained (approximately 5.8 kDa). Figure 2 shows an example of the MALDI-TOF 
spectrum, illustrating the supernatant sample of crude biosynthesised human insulin, which was 
induced at 1 mM IPTG. The results were confirmed using commercial human insulin as the sample 
using MALDI-TOF (Figure S2) and LC-MS (Figure S3). The LC-MS spectra detected the [M+4H]
4+
, 
[M+5H]
5+
, [M+6H]
6+,
 and M+7H]
7+
charged states of the human insulin protein in all IPTG induced 
samples (Figure S3). 
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Human insulin was detected in all the intracellular and inclusion body fractions under all IPTG 
induction conditions. Table 1 shows that 0.1 mM IPTG induced the optimum yield for recovering 
human insulin using the E. coli BL21 DE3-pET21b-hPin expression system, according to the standard 
curve using the commercially available standard human insulin (Figure S4). Most of the induced 
human insulin was in the intracellular (soluble) fraction, with 520.92 mg/L of human insulin received 
in the intracellular fraction for 0.1 mM IPTG induction; compared to 393.81 mg/L and 210.83 mg/L 
under 0.5 mM and 1.0 mM IPTG, respectively.  
 
Figure 2: A MALDI-TOF spectrum illustrating the supernatant sample of crude biosynthesised 
human insulin, which was induced at 1 mM IPTG. 
 
Table 1: The concentrations of human insulin obtained for the IPTG induction calculated based on commercial 
human insulin.  
 
IPTG induced sample 
Concentration (mg/L) 
(Intracellular) 
Concentration (mg/L) 
(Inclusion body) 
1 mM 210.83 65.45 
0.5 mM 393.81 64.20 
0.1 mM 520.92 107.82 
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3.3 Protein sequencing of induced biosynthesised human insulin 
 
The crude biosynthesised human insulin protein was sequenced. The standard human insulin was set 
as a positive control. The protein sequencing results confirmed that the biosynthesised protein was 
human insulin (Figure 3; Table S1). After a concatenated database search, the fragmented 
biosynthesised human insulin peptide sequence was found to have a 100% similarity match to that of 
the human insulin sequence from the protein database. 
 
 
Figure 3: A peptide spectrum illustrating the protein sequence of crude biosynthesised human insulin, 
which was a 100% match to the human insulin sequence derived from the Scaffold 1.4.4 software. 
 
3.4 Biological activity of human insulin 
 
The biological activity was tested using a MTT assay in vitro, using the HepG2 cell line under 
hyperglycaemic conditions (Figure 4). In the MTT assay, three concentrations were used of the 
standard human insulin and crude biosynthesised human insulin: low (50 μg/mL), medium (100 
μg/mL) and high (150 μg/mL). The results revealed that, for the low treatment the crude 
biosynthesised human insulin displayed higher cell viability than the standard human insulin; whereas 
the medium and high concentrations exhibited similar cell viability to that of the standard human 
insulin. The results were statistically significant with a calculated probability (p-value) of < 0,0001. 
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Figure 4: A graph illustrating the cell viability of HepG2 cells, under hyperglycaemic conditions for 
standard and crude biosynthesised human insulin at low (50 ng/mL), medium (100 ng/mL) and high 
(150 ng/mL) MTT concentrations (p-value < 0,0001).  
 
4 Discussion and conclusion 
 
This study developed a novel and efficient biosynthetic laboratory-scale method of human insulin 
production using an innovative recombinant cloning strategy, pET21b-hPin vector; and an E. coli 
BL21 (DE3) expression system was employed using proinsulin (Figure 2). Insulin can be 
biosynthesised using two methods. The first method is when the A and B chains of insulin are cloned 
separately, isolated, and subsequently purified as S-sulfonate derivatives. The chains are thereafter 
combined to form insulin, which is then purified (Kroef et al., 1989). The second approach involves 
the use of proinsulin, which is the preferred method of biosynthesising insulin, since a single 
fermentation is conducted, as opposed to in the first method of insulin production (Kroef et al., 1989). 
In terms of costs associated with affinity tag removal on a large scale, the current project was based 
on the biosynthesis and analysis of the untagged form of human insulin (Norouzi et al., 2016; Young 
et al., 2012). 
 
This study used a novel PCR-based strategy in the cloning of human insulin. The human insulin gene 
was amplified and confirmed using PCR (Figure S1). Subsequently, the pET21b-hPin plasmid was 
transformed into an expression host BL21 (DE3).  The production of biosynthesised human insulin 
was validated using MALDI-TOF-MS, LC-MS, and protein sequencing (Figure 3). Commercial 
human insulin was used as a positive control. 
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Mention is made in the literature of the human insulin protein being expressed at 1 mM IPTG 
(Redwan et al., 2007). In this study, the human insulin protein was initially induced with 1 mM IPTG 
at 37°C. Thereafter, the optimisation of the expression of human insulin was conducted, where the 
IPTG concentration was varied. The samples were detected using MALDI-TOF-MS (Figure 2) and 
LC-MS (Figure S3). A standard curve derived from various sample concentrations of standard human 
insulin was generated using MALDI-TOF-MS to extrapolate the respective protein concentrations 
from the biosynthesised human insulin supernatant and pellet fractions. The concentrations of the 
protein found in the intracellular fractions (soluble fractions) were 520.92 mg/L, 393.81 mg/L and 
210.83 mg/L; and in the pellets (inclusion body/insoluble fractions) they were 107.82 mg/L, 64.20 
mg/L and 65.45 mg/L for the respective IPTG concentrations of 0.1 mM, 0.5 mM and 1 mM (Table 
1). The optimum condition for the induction of human insulin was 0.1 mM IPTG.  
 
This study optimised human insulin protein expression, where the human insulin protein was 
expressed in the soluble (intracellular) fraction resulting in the elimination of the use of chaotropic 
agents. The use of chaotropic agents, such as urea and guanidine hydrochloride, can result in complete 
secondary structure denaturation (Singh et al., 2015). The use of guanidine hydrochloride and urea to 
solubilise protein results in a low yield of the bioactive therapeutic protein (Upadhyay et al., 2016). 
The proinsulin was produced in inclusion bodies at a 10% level in E. coli with a yield of 1.3 mg/L of 
insulin (Redwan et al., 2007). Solubilisation and refolding can often lead to poor recovery of the 
protein of the desired bioactive protein (Singh et al., 2015). This study had a yield of approximately 
520.92 (mg/L) of human insulin located in the intracellular (soluble) fraction, which is higher than in 
previous reports (Redwan et al., 2007). 
 
Researchers have found that protein expression conducted at a high inducer concentration and 
temperature resulted in the expression of the biosynthesised protein at an increased translational rate 
and can eventually result in the formation of inclusion bodies (Carrió and Villaverde, 2005). The 
formation of inclusion bodies in bacterial expression hosts such as E. coli presents challenges in the 
recovery process of bioactive proteins (Upadhyay et al., 2016). The extraction of recombinant 
biosynthesised proteins from inclusion bodies usually results in low yields of the bioactive protein, 
and this process is laborious (Singh et al., 2015). Inclusion bodies require downstream processing 
such as isolation from the cell, solubilisation, purification, and refolding of the protein (Redwan et al., 
2007; Singh et al., 2015; Zieliński et al., 2019). In this study, the protein was expressed mainly in the 
soluble fraction; therefore, the inclusion body recovery and renaturation of the protein steps were 
eliminated, which decreased the expenses associated with these steps. Therefore, the method of 
human insulin biosynthesis employed in this study is a more efficient process than the current 
methods (Zieliński et al., 2019).  
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The proinsulin cloning strategy uses the nucleotide sequence encoding for human proinsulin, which 
consisted of A, B, and C chains (Chance et al., 1999). In the above strategy, proinsulin was cloned, 
and the C-peptide was cleaved using Achromabacter lyticus protease, carboxypeptidase B, and trypsin 
(Baeshen et al., 2014; Mollerup et al., 2009; Morihara et al., 1980). Achromobacter lyticus protease 
(Morihara et al. 1980) is a lysine-specific enzyme which can enzymatically convert proinsulin to 
insulin; it has an advantage over trypsin digestion as it avoids non-specific cleavage after the arginine 
at position B22 (Mollerup et al., 2009). The C-peptide bond was enzymatically cleaved by the 
utilisation of cyanogen bromide; this was followed by protein folding and the formation of disulphide 
bonds (Frank and Chance, 1983). The enzymes that are normally used in the C-peptide cleavage, such 
as carboxypeptidase B, are costly (Redwan et al., 2007). This ground-breaking study eliminated the 
expensive digestion of the C-peptide, which occurred as a result of autocatalytic cleavage (Gooch, 
2011). 
 
The human insulin that was biosynthesised in this study was detected and verified using MALDI-
TOF-MS, LC-MS, and protein sequencing. Standard human insulin served as a positive control for the 
protein sequencing of human insulin with a 90% similarity to the human insulin sequence from the 
protein database (Figure S5). The crude biosynthesised human insulin protein produced in this study 
was verified using protein sequencing. After a concatenated peptide database search, the crude 
biosynthesised human insulin was unequivocally proven to be human insulin with a 100% similarity 
(Figure 3). Therefore, this study successfully biosynthesised and optimised the expression of human 
insulin in E. coli.  
 
This study employed an in vitro MTT assay to determine the biological activity. The MTT assay is 
used to measure the viability of metabolically active cells based on the cells’ ability to produce 
reducing equivalents (Carrió and Villaverde, 2005; Morihara et al., 1980). The cell uptake of MTT by 
a protein facilitated mechanism or by endocytosis leads to the reduction of MTT. This yields a purple 
formazan product, which is impermeable to cell membranes and results in its accumulation within 
living cells (Hansen and Bross, 2010; Maioli et al., 2009; Mosmann, 1983). The solubilisation of the 
cells results in the release of the purple product, which is detected colorimetrically (Maioli et al., 
2009). The cells' respiratory chain (Slater et al., 1963) and other electron transport systems (Liu et al., 
1997) cause the reduction of MTT. The reduction of MTT by living cells is an indication of 
mitochondrial activity, which therefore serves as a measure of cell viability (Maioli et al., 2009). 
Insulin is involved in the regulation of glucose uptake into muscle and fat cells (Drejer, 1992). Insulin 
works within seconds to activate the tyrosine kinase receptor, ion transport systems, and stimulation 
of glucose (Drejer, 1992). Therefore, the glucose utilisation by the HepG2 cells increases cellular 
respiration and mitochondrial activity, increasing cell viability. The biological activity was tested in 
this study using a MTT assay in vitro, using a HepG2 cell line with normoglycaemic (5.5 mM) and 
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hyperglycaemic (25 mM) conditions (Chen et al., 2006). The MTT assay exhibited increased cell 
viability in the hyperglycaemic treatments. There were three treatment concentrations of standard 
human insulin and crude biosynthesised human insulin: low (50 ng/mL), medium (100 ng/mL), and 
high (150 ng/mL). The analysis was conducted on standard human insulin and biosynthesised human 
insulin. The standard human insulin served as a positive control. The cell viability of the crude 
biosynthesised human insulin showed (288,42% ± 9,04%) low, (254,57% ± 12,96%) medium and 
(358,70% ± 24,17%) high concentrations, in comparison to standard human insulin which had 
(257,37% ± 29,65%) low, (265,23% ± 23,61%) medium and (358,07% ± 33,10%) high 
concentrations. In the low concentration, the crude biosynthesised human insulin displayed higher cell 
viability than the standard human insulin; whereas the medium and high concentrations exhibited 
similar cell viability to that of the standard human insulin. As such, the efficacy was determined to be 
the same as the standard human insulin. Therefore, we can conclude that the novel method employed 
in this study is an efficient and effective method of human insulin production.  
 
The biological activity test conducted in this study revealed that the crude biosynthesised human 
insulin displays similar efficacy to that of the commercially available standard human insulin. This 
study successfully provided a novel method for the biosynthesis of human insulin since it employed 
the untagged pET21b expression vector in E. coli. The elimination of affinity tags has implications 
with regards to protein purification, as well as the reduction in downstream processing costs, such as 
glutathione S-transferase and histidine tag removal. In addition, this method also eliminated the 
tedious protein enzymatic cleavage of the C-peptide, the recovery of human insulin from inclusion 
bodies, and human insulin renaturation steps; thereby making this process less labour-intensive. This 
study was conducted on a laboratory-scale; however, it has the potential to be up-scaled industrially. 
Future studies can focus on finding greener and more affordable purification methods for human 
insulin. 
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Abstract 
 
There is a paucity of knowledge surrounding the SFC purification of human insulin. The current 
conventional method of insulin purification involves traditional RP-HPLC that utilises copious 
amounts of toxic solvents. In this study, we envisaged the development of an environmentally friendly 
SFC method for biosynthesised human insulin purification. Various commercially available SFC 
columns derived with silica, 2’ethyl pyridine, diol-HILIC, and the PFP functionalities were evaluated 
to determine the optimal stationary phase for purification. The PFP column gave the best results with 
respect to efficiencies of this important biologic that yielded average recoveries of 84%. LC-MS was 
used to initially detect and quantify the SFC purified standard sample of insulin (purchased) as well as 
the biosynthesised version. Protein sequencing was employed to verify the amino acid sequencing of 
the insulins; as such, the standard had a 90% probability to human insulin from the database, whereas 
the biosynthesised version had a 96% probability. The biological activities of both versions of the 
SFC purified proteins were assessed in vitro using a MTT assay. The results indicated that the 
biological activities of both samples were retained post-SFC purification. This study successfully 
proposes a greener and more efficient method for the purification of insulin derivatives.  
 
 
Keywords: human insulin; sub/supercritical fluid chromatography purification. 
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1 Introduction 
 
Human insulin is generally purified via a three-step approach comprising of ion exchange, size 
exclusion, and reversed-phase high-performance liquid chromatography (RP-HPLC) chromatography 
[1, 2]. The large scale pharmaceutical purification of biosynthesised insulin derived from recombinant 
deoxyribonucleic acid (DNA) technology is conventionally purified using preparative RP-HPLC 
methods [2]. This approach usually results in yields of approximately ≥ 75% on C18 [3] and C8 [2] 
stationary phase columns. In conventional analytical separations conducted via RP-HPLC, acetonitrile 
is employed as the mobile phase with flow rates of 1.0 mL/minute, and as much as 50 mL of waste is 
generated per run [2, 4]. In 2019, approximately 463 million people were diagnosed with Type 2 
diabetes. If all of these patients are treated with insulin twice a day with the basal insulin treatment 
method of 0.1 units/kg/day, approximately 1.25 × 10
8
 litres of acetonitrile would be generated in a 
year [2, 5-7]. Acetonitrile is the most extensively used organic solvent in RP-HPLC; however, the 
waste generation has a negative impact on the environment [8-10]. Apart from having a poor 
environmental profile, it’s waste disposal also presents challenges, and it is also expensive [11, 12]. 
Therefore, there is a need for “greener” separation and purification processes that produce less waste 
and utilise more environmentally friendly solvents [4, 10, 13, 14].  
 
SFC (sub/supercritical fluid chromatography) has been extensively used as analytical, semi-
preparative, and preparative tools in the pharmaceutical industry over conventional HPLC for the 
separation of chiral compounds “[15-20]” and “peptides” [18, 21, 22]. SFC is gaining significant 
momentum in the pharmaceutical industry as it is a robust and powerful method that is well 
established for the rapid separation of enantiomers, with a two-fold reduction in time relative to 
conventional chiral phase HPLC [23-28]. It has numerous advantages such as better reproducibility, 
faster equilibration, and shorter run times, thereby increasing chromatographic productivity while 
reducing solvent consumption and waste [29-32]. SFC is considered to be environmentally friendly as 
the carbon dioxide (CO2) used as the major mobile phase and can be efficiently recycled [30, 33].  
 
Schiavone, et al. reported the SFC purification of commercially available bovine insulin as well as 
other proteins such as ubiquitin, cytochrome C, and apomyoglobin [34]. They employed techniques 
such as size exclusion chromatography coupled with hydrogen deuterium exchange (SEC-HDX) 
technology to monitor the after-effects of the SFC purification on the aforementioned proteins. The 
results indicated that the insulin could withstand the SFC conditions as the higher order structure was 
retained, but the same was not observed for ubiquitin, cytochrome C, and apomyoglobin, which could 
not re-fold to their original conformations post-SFC. 
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A major bottleneck in the drug development process is the purification of complex polar mixtures; 
therefore, new SFC techniques are required to increase respective analytes throughput, enabling 
efficient separations which expand the SFC applications to more polar biologic analytes [22, 35]. 
Studies have indicated that the addition of small amounts of water to the CO2/methanol modifier has 
shown to enhance SFC chromatography by improving analytes solubility, peak shapes, allows for the 
separation of more polar analytes, a decrease in run times and enables a greener SFC purification 
process as less organic solvent is consumed [22, 34-37]. In our study, we demonstrated the effect of 
combining water with methanol, trifluoroacetic acid (TFA), and CO2 modifier to enable the SFC 
purification of biosynthesised human insulin. 
 
We aimed to develop a method for the purification of human insulin utilising SFC as opposed to the 
conventional established RP-HPLC approach [38]. Herein, an innovative insulin purification method 
is reported utilising SFC technology to purify crude biosynthesised human insulin at a semi-
preparative scale. The standard (purchased) and the biosynthesised samples of insulin were quantified 
and characterised using liquid chromatography-mass spectrometry (LC-MS).  
 
In this study also employed protein sequencing to validate that the purchased standard and 
biosynthesised samples were indeed human insulin derivatives. Organic solvents such as alcohols 
(which were used as modifiers) can cause the complete unfolding of a protein (denaturation), resulting 
in the formation of precipitates or aggregates [34, 39, 40]. Furthermore, the biological activities of the 
proteins after purification were evaluated to determine the effects of the SFC conditions on their 
structure employing an in vitro 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) assay. The post evaluation was important since the protein has a tendency to form insoluble 
precipitates when exposed to heat or hydrophobic surfaces. Therefore, this study will investigate the 
SFC purification of human insulin analogues and, thereafter, assess their biological activities. 
 
2 Materials and methods 
 
2.1 Chemicals and reagents 
 
The standard sample of human insulin (catalogue number: I2643) was purchased from Sigma-Aldrich 
Inc. (Germany). The biosynthesised sample of the insulin employed in this study was genetically 
engineered via recombinant DNA technology utilising E. coli [41]. RP-HPLC grade acetonitrile, 
methanol, formic acid, and TFA were purchased from (Merck, Germany). Ultrapure water was 
obtained from a Millipore Milli-Q Gradient (Millipore, USA) water purification system. The 
hepatocellular carcinoma (HepG2) cell line was procured from Highveld Biologicals (South Africa), 
and the cell culture reagents were obtained from Whitehead Scientific (South Africa).  
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All other reagents were purchased from Merck (Germany) unless stated otherwise. The following 
SFC columns were employed in this study for the SFC purification of the biosynthesised human 
insulin: silica (250 mm × 4.6 mm; particle size 5 μm, Supelco™, USA), 2’ ethyl pyridine (250 mm × 
4.6 mm; particle size 5 μm, Princeton chromatography Inc., USA), diol-Hydrophilic interaction liquid 
chromatography (HILIC) (250 mm × 4.6 mm; particle size 5 μm, YMC, Japan) and pentafluoro 
phenyl (PFP) (250 mm × 4.6 mm; particle size 5 μm, YMC, Japan). 
 
2.2  SFC purification  
 
SFC purifications were conducted on a Sepiatec Prep SFC 30 system (Sepiatec, Germany). The SFC 
instrument comprised of a high-pressure pump, a back-pressure regulator, an injector with an injection 
loop, column oven and an ultraviolet (UV) detector. The UV detector was set at a wavelength of 220 
nanometres (nm). The column oven temperature was maintained at 40°C, and injection volumes of 50 
μL were used. The CO2 pump head was cooled with a chiller, which was set at 5°C (PolyScience, 
USA). Various isocratic and gradient conditions were investigated. The mobile phases used were 
technical grade CO2 (Afrox, South Africa) and a methanol modifier (Merck, Germany) that contained 
5% (v/v) water and 0.2% (v/v) TFA. The gradient profile was 5-60%, whereby the modifier was 
initially held at 5% for one minute and thereafter increased to 60% over 6 minutes and maintained for 
a further 5 minutes. Flow rates of 4 mL/minute were optimal for all columns, with a total run time of 
approximately 13 minutes. Isocratic SFC conditions were conducted with a 10% modifier for 
approximately 10 minutes. After fraction collection, the standard and the biosynthesised samples were 
spun down using a rotary evaporator (Heidolph, Germany) and carefully transferred to 
microcentrifuge tubes (ISOLAB Laborgerate GmbH, Germany). The samples were freeze-dried 
overnight using a FreeZone 4.5 litre freeze drier (Labconco, USA).   
 
2.3 LC-MS monitoring 
 
A LC-MS-2020 (Shimadzu, Japan) was used to determine the purities of both the crude and purified 
samples. Injection volumes of 10 μL of unpurified standard (1 mg/mL) and crude biosynthesised 
human insulin (0.52 mg/mL) were used. However, post-SFC, in the LC-MS analysis, the injection 
volumes were increased to 50 μL of the samples. The LC-MS was coupled to a NM32LA nitrogen 
generator (Peak Scientific Instruments, United Kingdom). There were two mobile phases employed in 
the LC-MS analyses; mobile phase A consisted of Millipore water (Millipore, USA) and mobile phase 
B comprised of acetonitrile (Merck, Germany). The mobile phases above both contained 0.1% (v/v) 
formic acid, which served as an ion-pairing agent, with 1.0 mL/minute flow rates and run times of 25 
minutes.  
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A 5% to 95% acetonitrile gradient was conducted; it was equilibrated for approximately 7 minutes at 
5% acetonitrile, and thereafter ramped up to 95% over 18 minutes. A YMC-Triart C18 (YMC, Japan) 
stainless steel column was employed for the LC-MS analysis, which contained the dimensions of 4.6 
mm internal diameter (ID), a pore size of 120 Å with a particle size of 5 μm and a length of 150 mm. 
The temperature of the column was maintained at 40°C. The MS spectra were obtained using a mass 
range of 200 to 1500 m/z in a positive mode. The desolvation gas temperature was 250°C. The dry 
gas had a 10 L/minute flow rate, and the nebuliser was set at 1.5 bar. 
 
2.4 Protein sequencing of insulin 
 
The standard (purchased) and the biosynthesised samples of insulin were analysed at the Central 
Analytical Facility (Stellenbosch University, South Africa) [42] using LC-MS/MS conducted on an 
Ultimate 3000 RSLC (Thermo Fisher Scientific, USA) coupled to a Fusion mass spectrometer 
(Thermo Fisher Scientific, USA), via nano ionisation source (Nanospray Flex). The mass 
spectrometer files were subsequently imported onto the Proteome Discoverer v1.4 according to the 
manufacturer’s instructions (Thermo Fisher Scientific, USA) and analysed using Sequest and an 
Amanda algorithm. The Uniprot P09211 linked to the contaminant protein database (cRAP) was used 
whereby a concatenated database interrogation was conducted. The peptides were validated using 
Target-Decoy PSM validator mode. The peptides were validated and identified using Protein Prophet 
and X! Tandem algorithms from the Scaffold 1.4.4 software (Proteome Software Inc, USA) according 
to the manufacturer’s instructions. 
 
2.5 Biological activity of insulin 
 
A MTT assay was used to determine the biological activities of the standard and the biosynthesised 
insulin samples in vitro. HepG2 cell lines were employed in this study and were grown according to a 
similar method reported by Abdul et al., 2016 [43]. The standard and the biosynthesised insulin stock 
solutions were made in Eagle's minimum essential medium (EMEM) (catalogue number: 12-136F, 
Lonza, Switzerland) up to a concentration of 1 mg/mL. Three concentrations of the standard and 
biosynthesised samples of the insulin [low (50 μg/mL), medium (100 μg/mL), and high (150 μg/mL)] 
were used in the MTT assays.  
 
The cells were grown on a 96-well plate for 24 hours (2x10
4 
cells/well) followed by removal of the 
culture medium cells washed with phosphate-buffered saline (PBS). The HepG2 cells were 
subsequently treated with either the standard or biosynthesised samples of insulin prior to SFC 
purifications in normoglycaemic (5.5 mM) and hyperglycaemic (25 mM) media [44] for 15 minutes.  
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The above process was also conducted after SFC purifications for both the standard and the 
biosynthesised samples of the insulin. Thereafter, the cells were washed in PBS and 120 µl of MTT (5 
mg/ml, PBS) and incubated for 4 hours at 37°C. Formazan crystals were solubilised via the addition 
of 100 µl of dimethyl sulfoxide (DMSO) per well, and optical densities (OD) were measured 
spectrophotometrically (BioTek uQuant, USA) at a wavelength of 570 nm. The experiments were 
conducted in triplicate. 
 
The following formula was used to calculate cell viability (%): 
 
% Cell viability =
OD of treated cells
OD of control cells
  × 100 
 
2.6 Statistical analyses 
 
A two-way analysis of variance (ANOVA) was employed in this study. Analyses were conducted 
using the statistical software package Graph pad in stat version 8.1.0 (325) 64 bit for Windows (Graph 
pad software, San Diego, California). 
 
3 Results and discussion 
 
3.1  SFC results: column optimisation 
 
Currently, there is limited information regarding SFC purification of insulin. However, as already 
mentioned, there is one recent report in which commercially available bovine insulin was purified 
using SFC on a preparative scale, and they reported the use of a 2’picolylamine column, with a 
mixture of acetonitrile and methanol as the modifier [34]. In our study, standard and crude 
biosynthesised human insulin derivatives were purified using SFC on a semi-preparative scale. The 
use of acetonitrile was eliminated due to its toxicity, therefore, making this a “greener” purification 
process [45]. LC-MS analysis, protein sequencing, and an in vitro MTT assays were employed in 
order to monitor both the standard and crude biosynthesised insulin derivatives post-SFC purification.  
 
The characteristics of a protein play a fundamental role in its purification process and include its total 
charge, number of exposed hydrophobic groups, its binding capacity to the stationary phase as well as 
its shape, and size [46]. The selection of the correct stationary phase is imperative in the method 
development stages of SFC purifications. Proteins can interact with the chromatographic stationary 
phases in a variety of manners, whereby the retention times are affected by the protein's molecular 
composition [47].  
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Studies have indicated that to separate and purify strongly polar molecules, the addition of water can 
improve the molecule's solubility, peak shapes, chromatographic selectivity and speed [22, 34-37, 48, 
49]. In this study, we implemented the addition of 5% (v/v) water to methanol with 0.2% (v/v) TFA 
and technical grade CO2 to enable the SFC purification of human insulin. Initially the standard sample 
of insulin (1 mg/mL) was dissolved in 50% (v/v) water and 50% (v/v) methanol with 0.2 % (v/v) 
formic acid. The initial conditions for the evaluation of all of the columns employed a gradient 
method of 5-60% of the modifier over 13 minutes and the silica, diol-HILIC, 2’ ethyl pyridine, and 
PFP columns were used for the initial screening of conditions. With the silica column, four peaks 
were observed with relatively long retention times, poor peak resolution, and high baseline noise 
leading us to believe that the protein was not eluted from the column (Figure 1-A). The 2’ ethyl 
pyridine column displayed similar properties to that of the silica column (Figure 1-B). The diol-HILIC 
column had two peaks with good UV intensities (Figure 1-C), and the LC-MS analysis of both peaks 
(upon separation) gave the same retention times and masses when exposed to RP-HPLC (Figures S1 
and S2 in the supporting information). This observation can be attributed to the protein separation of 
secondary structures that occurred between the protein and the packing material due to adsorption 
effects [50, 51]. Therefore, the PFP column was selected for further purification and optimisations of 
the biosynthesised sample of the insulin, as it displayed relatively better properties such as peak 
shapes, resolution, retention factors, retention times and the least relative standard deviation in 
comparison to the other columns (refer to Figure 1-D, Tables 1 and S1). This column is known for 
displaying ion-exchange, dipole-dipole, and π-π interactions with a variety of analytes as well as 
being highly stable [52, 53]. Subsequently, we optimised the method to even work well under 
isocratic conditions with a 10% methanol modifier that contains 5% (v/v) water and 0.2% (v/v) TFA 
(Figure S3). Isocratic conditions are preferred for stacked injections, as this is one of the main 
advantages of SFC protocols [24, 26]. 
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Figure 1: Represents SFC chromatograms of the standard sample of insulin (1 mg/mL) on analytical 
size columns (250 mm × 4.6 mm): (A) silica column (B) 2’ethyl pyridine (C) diol-HILIC (D) PFP. 
All columns were run using a gradient mode with a modifier range of 5-60%. 
 
Table 1: Retention factors (k) of the standard sample of insulin (1 mg/mL). 
 
Column k1 k2 k3 k4 Assessment of column  
silica  4.1 6.0 6.9 10 Long retention times, poor peak resolution and baseline 
noise 
2’ ethyl 
pyridine 
10.6 12.0 - - Long retention times, baseline noise, poor peak shapes 
and peak resolution 
diol-HILIC 4.7 7.9 - - Poor peak shape and peak splitting 
PFP 3.9 8.4 - - No peak splitting, good peak shape, and resolution 
 
In an attempt to eliminate the phase separation peak and band broadening anomalies experienced 
during the SFC purification, various combinations of acids such as formic acid, acetic acid, and 
organic solvents such as DMSO as well as hexafluoro isopropanol (HFIP) were combined with 
methanol (Figure S4) while optimisation with the standard insulin sample. The use of HFIP and 
methanol was successful in the elimination of the phase separation peak for the standard sample and 
was the best condition in comparison to the former conditions (Figure S4).  
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3.2 PFP column efficiency test of the biosynthesised sample of insulin 
 
Although a mixture of HFIP and methanol was used to dissolve the standard sample, Tris-HCl was 
required for the biosynthesised samples, since precipitation occurred under the former conditions and 
was probably due to the solubilities of some other proteins. This resulted in inaccurate total protein 
concentration determinations. This is a common effect as alcohol tends to denature some proteins 
[40]. Fortunately, Tris-HCl worked well for both the solubilisation of the standard and the 
biosynthesised samples while also the best condition to prevent the occurrence of phase separation 
peaks (Figures S3 and S5). With the optimised conditions in hand, the purification of the 
biosynthesised sample of insulin was attempted. PFP column efficiency tests were conducted using 
the biosynthesised sample, which yielded an average recovery of 84% (Figure 2-B). The weights of 
the freeze-dried samples were recorded; a PFP column efficiency test was determined according to the 
following equation: 
 
Column efficiency =
Freeze − dried weight of biosynthesised sample after SFC purification     
Freeze − dried weight of biosynthesised sample before SFC purification
 × 100     
 
=
17.8 mg 
  21.1 mg
 × 100 
 
= 84.36% 
 
3.3  LC-MS mass spectra and protein sequencing of insulin 
 
The standard, as well as the biosynthesised samples of insulin, were detected and confirmed using 
LC-MS analysis. The retention time for the standard sample of insulin was 12.5 minutes (Figures S6). 
The crude biosynthesised sample had numerous peaks before SFC purification which was indicative 
of the presence of numerous other proteins with a purity of approximately 19% (Figure 2-A); 
however, after SFC purification, there was one peak present at a retention time of 12.9 minutes with a 
purity of approximately 85% (LC-MS) therefore indicating the SFC purification was successful 
(Figure 3). The difference in retention times was attributed to the differences in sequences of insulin 
derivatives. The observed masses were validated with LC-MS, whereby the commercially available 
standard sample of insulin was 968.87 m/z (Figure S6), and the biosynthesised sample had a mass of 
968.08 m/z. (Figure 3). The standard sample of insulin had a 90% probability to the human insulin 
from the database used for the protein sequencing (Figure 4, Tables S2 and S3), whereas the 
biosynthesised version had a 96% probability (Figure 5, Tables S4 and S5). 
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Figure 2: A Represents a LC-MS spectrum obtained from a YMC-Triart C18 (dimensions: 150 mm × 
4.6 mm (length x internal diameter), pore size: 120 Å, and a particle size of 5 μm) of the crude 
biosynthesised sample of insulin and B represents SFC chromatograms of the crude biosynthesised 
sample of insulin, which was separated on a PFP based column with the following characteristics; 
dimensions: 250 mm × 4.6 mm (length x internal diameter), pore size: 120 Å and a particle size of 5 
μm.  
 
 
 
Figure 3: Represents a LC-MS spectrum obtained from a YMC-Triart C18 (dimensions: 150 mm × 4.6 
mm (length x internal diameter), pore size: 120 Å, and a particle size of 5 μm) of SFC purified 
biosynthesised sample of insulin. 
 
 
Figure 4: A peptide spectrum illustrating  the standard sample of insulin, which had a 90% peptide 
sequence probability to human insulin derived from the Scaffold 1.4.4 software (Central Analytical 
Facility, Stellenbosch University, South Africa) [42]. 
 
 
    
A B 
Desired 
peak Desired peak 
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Figure 5: A peptide spectrum illustrating the biosynthesised sample of insulin after SFC purification 
with a 96% probability in peptide sequence to human insulin derived from the Scaffold 1.4.4 software 
(Central Analytical Facility, Stellenbosch University, South Africa) [42]. 
 
In this study, the standard sample of insulin was employed as a control for the optimisation of the SFC 
conditions of a biosynthesised insulin analogue. Insulin is an unstable entity as it can undergo various 
modifications, such as chemical reactions with surrounding molecules and proteins that are prone to 
denaturation during handling in the pharmaceutic industry [54]. Denaturation can also be caused by 
organic solvents, heating, freezing, pH extremes, and denaturants [55, 56]. Proteins undergo 
conformational changes with high temperature [57]. Proteins will also precipitate in high 
concentrations of organic solvents, such as alcohol [58]. Proteins are labile under high temperatures, 
and this can compromise biological activities and tertiary structures [58]. In this study, insulin was 
exposed to increased temperature (40°C) as well as alcohol, such as methanol under the SFC 
conditions (up to 260 bars of pressure). Therefore, the biological activity of the biosynthesised sample 
of insulin was tested in vitro using a MTT assay to determine the effect of SFC purification. The 
standard sample of insulin was utilised as a positive control in the MTT cell viability assay (Figure 6).   
 
3.4 Determination of biological activities of insulin via a MTT assay 
 
The MTT assay measures metabolically active cell viabilities, which is based on the cells’ ability to 
produce reducing equivalents [59, 60]. The metabolically active cells uptake MTT by endocytosis or 
via a protein facilitated mechanism and results in the formation of a purple formazan product, which 
accumulates within living cells [60-62]. The metabolism of the dye releases the purple formazan 
product, which is quantified via colorimetric analysis [61]. MTT is reduced in metabolically active 
cells by the cells’ electron transport systems [63] and respiratory chain [64].  
 
The HepG2 cell line was grown under normoglycaemic (5.5 mM) and hyperglycaemic (25 mM) 
treatment conditions [44]. The MTT assay was employed to measure the cell viabilities of 
metabolically active cells based on their ability to produce reducing equivalents [65, 66]. Insulin is 
associated with the regulation of glucose uptake into muscle and fat cells and works within seconds to 
activate the tyrosine kinase receptor and the stimulation of glucose [67].  
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The glucose utilisation by the HepG2 cells increases cellular respiration and mitochondrial activities, 
increasing cell viabilities. The MTT assay results correlated with the former observation and showed 
an increase in cell viabilities for the hyperglycaemic treatments. Three treatment concentrations; low 
(50 ng/mL), medium (100 ng/mL) and high (150 ng/mL) were evaluated. The analyses were 
conducted using crude biosynthesised samples, and SFC purified biosynthesised samples of insulin. 
The cell viabilities of the SFC purified standard samples for the low, medium, and high concentrations 
were 219.79% ± 72.40%, 258.76% ± 25.83%, 356.35% ± 14.28% respectively. The cell viabilities of 
the SFC purified biosynthesised analogue were 260.15% ± 3.02%, 358.13% ± 17.00%, 350.24% ± 
44.16% for the low, medium and high concentrations respectively (refer to Figure 6 and Figure 7). 
Both SFC insulin analogues exhibited similar cell viabilities to that of post-SFC purifications. As 
such, the MTT assay results revealed that the biological activities were retained after SFC 
purifications in all three concentrations. Future studies can investigate the use of ion mobility-mass 
spectrometry for analysis of samples post SFC [68, 69]. 
 
This study proves that SFC purification could be employed for the purification of insulin derivatives 
and provides a suitable alternative to RP-HPLC. In this study, the PFP column efficiency test yielded 
a recovery of 84% compared to traditional RP-HPLC methods of ≥ 75% [2]. The SFC run time was 
decreased to approximately 10 minutes (isocratic conditions, Figure S3) as compared to the traditional 
RP-HPLC of 50 minutes, which was conducted at an analytical scale [2]. This drastic reduction in 
time would decrease the amount of solvents being used in the overall purification process of insulin; 
therefore, this study reduced the carbon footprint of biosynthesised insulin.  
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Figure 6: A graph displaying the cell viabilities of HepG2 cells, under normoglycaemic (NG) and 
hyperglycaemic (HG) conditions for low (50 ng/mL), medium (100 ng/mL) and high (150 ng/mL) 
MTT concentrations treated with standard insulin sample before SFC purification and after SFC 
purification (p-value < 0.0001).  
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Biosynthesised human insulin
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Figure 7: A graph displaying the cell viabilities of HepG2 cells, under normoglycaemic (NG) and 
hyperglycaemic (HG) conditions under low (50 ng/mL), medium (100 ng/mL) and high (150 ng/mL) 
MTT concentrations treated with biosynthesised insulin sample before SFC purification and after SFC 
purification (p-value < 0.0001). 
 
4 Conclusion 
 
In 2019 the number of adults with Type 2 diabetes was approximately 463 million; it is projected to 
increase to approximately 700 million by 2045 [8]. The rapid rise in patients with diabetes globally 
creates a severe demand for affordable insulin. This study successfully shows that SFC technology 
can be employed as a rapid, cost-effective, and greener method of purifying biosynthesised insulin as 
opposed to using conventional HPLC. Several SFC columns were assessed, and the PFP column gave 
the best results since it displayed good peak shapes, resolution, retention factors, retention times, and 
the least relative standard deviation in comparison to the other columns. Initially, the conditions for 
the purification were optimised using a standard sample. Thereafter, column efficiency tests were 
conducted at an analytical scale, yielding 84% recovery of the biosynthesised sample. The biological 
activity of the biosynthesised insulin analogue was determined using a MTT cytotoxicity assay after 
SFC purification with excellent retention of activity. The biological activities were highly significant, 
with a p-value of < 0.0001. Since the recovery from the SFC column was 84%, future endeavours for 
improvement of this method can implement the use of custom columns. In addition, the modifier 
effects, band broadening, and phase separation peaks are areas of development for industrial 
innovators. Future research can also investigate the use of different modifiers to determine its effect 
on the solubility of various proteins. This work serves as a proof-of-concept starting point and forms 
one of only two reports on the purification of biologically important proteins using cutting edge SFC 
technology. 
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Abstract 
 
Peptide drugs are essential components of the pharmaceutical industry with a multiplicity of 
therapeutic properties, such as being anti-hypertensive, anti-microbial, anti-diabetic, and anti-cancer. 
These molecules are similar in physiological structure and function to the body’s endogenous 
signalling molecules and are therefore ideal candidates for the development of the next generation of 
drugs. However, the purification of these peptides can be problematic due to poor solubility and 
stability, which often results in low peptide yields. Peptides are traditionally purified via RP-HPLC 
methods, which are tedious and employ harsh solvents that generate harmful waste to the 
environment. There is a growing need for more cost-effective and sustainable purification methods of 
these biologics. SFC can provide a greener peptide purification approach with more environmentally 
friendly mobile phases such as CO2 and methanol, which can easily be recycled with minimal 
environmental impact. Currently, there is limited knowledge regarding the SFC purification of 
peptides. Herein, this study investigated SFC methods to purify a tetrapeptide (LYLV), octapeptide 
(DRVYIHPF), and nonapeptide (LYLVCGERG) on commercially available columns at an analytical 
scale. The 2’ ethyl pyridine column proved to be optimal based on its reproducibility, peak shapes, 
efficient separations, and retention factors with peptide recoveries ranging from 80-102%. The run 
times were reduced to 13 minutes, as opposed to the traditional RP-HPLC methods of 50 minutes, 
thus making this SFC method an efficient, greener, and more cost-effective approach for the 
purification of these peptides. 
 
Keywords: Sub/supercritical fluid chromatography (SFC); PFP column; diol-HILIC column; 2’ ethyl 
pyridine column; tetrapeptide [insulin β chain peptide (15-18)]; octapeptide [angiotensin II]; 
nonapeptide [insulin β chain peptide (15-23)]. 
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1 Introduction  
 
Peptides are a privileged class of pharmaceutical biologics that display distinct therapeutic and 
biochemical properties [1]. Advances in genomics, transcriptomics, proteomics, and protein 
engineering have resulted in the synthesis of peptides with similar molecular structures to that of 
endogenous signalling compounds in the body, such as neurotransmitters [2-5]. Peptides are 
extremely versatile, with several medicinal benefits ranging from anti-viral, anti-diabetic, anti-cancer, 
and anti-microbial properties [6-8]. The physiochemical characteristics of peptides are that of being 
relatively small in size while displaying structural diversities, low toxicities, high biological activities, 
high tissue affinities, and specificities [9-11]. Peptides are postulated to be the next-generation of 
highly prescribed drugs, as exemplified by their already routine use in several major diseases [6, 11-
15].  
 
There are several problems associated with the mass production of peptides, such as the high costs 
concerning the synthesis and especially the purification [12]. Currently, the purification of peptides 
are effected using a range of chromatographic methods, including reversed-phase high-performance 
liquid chromatography (RP-HPLC) [16-20], size exclusion chromatography (SEC) [16, 19-21], and 
ion-exchange chromatography (IEC) [16, 19, 20, 22]. These methods are normally lengthy and costly 
[19, 23-26]. This is a major bottleneck that is commonly experienced during the production of peptide 
therapeutics [8, 12]. Conventional analytical separations generate approximately 60 mL's of waste per 
run that is potentially hazardous to the environment and increases operating costs [20, 25-28]. 
Another major problem is associated with the solubilities and stabilities of these compounds during 
the purification processes [12]. Consequently, there is a need for more greener and environmentally 
friendly processes [26, 29-32]. 
 
Purification via sub/supercritical fluid chromatography (SFC) of such compounds may provide a 
possible solution, with a considerable gain in the momentum of this technique in the pharmaceutical 
industry in recent times [16, 33-36]. Essentially, SFC can reduce the amount of organic solvents being 
used during the purification processes since it employs carbon dioxide (CO2) as the major mobile 
phase, thereby resulting in less energy being consumed during the evaporation and fractionation 
processes [37]. The separation of drugs on the SFC has proven to have higher efficiencies, faster run 
times, and stacked injections, which allows for higher chromatographic productivities and the 
reduction of solvent waste [16, 33, 34, 38-44]. However, there are also disadvantages associated with 
SFC purification, for example, the mismatch of modifiers utilised to dissolve the analyte and the 
mobile phase employed, which can result in broad peak profiles [33, 45]. Currently, there is limited 
information regarding the SFC purification of biomolecules, such as proteins and peptides. However, 
there was a recent study by Schiavone et al. in which they reported the successful preparative scale 
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SFC purification of bradykinin (peptide) and commercially available proteins such as bovine insulin, 
ubiquitin, and cytochrome C [16]. The aforementioned study employed a 2’picolylamine column with 
CO2 and a mixture of acetonitrile and methanol together with 5% H2O and 0.2% trifluoroacetic acid 
(TFA) additives as a modifier [16]. However, the potential drawbacks of the aforementioned study 
were that the higher-order structures of ubiquitin, cytochrome C, and apomyoglobin were not retained 
after SFC purification. Schiavone et al. concluded that the bradykinin and the bovine insulin can be 
purified using this method since insulin’s higher-order structures were retained post-SFC [16]. 
Another study conducted by Tognatelli et al. employed SFC on an analytical scale using a 2’ethyl 
pyridine column whereby they successfully purified a mixture of peptides such as G3502, V8376, 
methionine encephalin acetate, angiotensin II acetate, and leucine encephalin acetate and utilised CO2 
and methanol as a modifier with 0.1% TFA [25].  
 
A major bottleneck in the drug development process is the purification of polar mixtures; therefore, it 
is imperative that new SFC techniques are developed, which expand SFC purification to more polar 
analytes [33, 35, 46]. Studies have shown that the addition of small amounts of water to the methanol/ 
CO2 modifier has enhanced SFC chromatography by improving analytes solubility and aids in the 
separation of more polar analytes [16, 33, 35, 46-48]. Therefore, in our study, we demonstrated the 
effect of combining water with methanol, TFA, and CO2 modifier to enable the SFC purification of 
crude peptides. 
 
Our study aimed to build on this developing field and employed peptides associated with diabetes and 
cardiovascular diseases by also evaluating SFC technology of some commercially available columns 
at an analytical scale. The following analytes were selected as candidates since these peptides are 
commonly used in the treatment of non-communicable diseases, a tetrapeptide [insulin β chain 
peptide (15-18)], octapeptide [angiotensin II], and a nonapeptide [insulin β chain peptide (15-23)][49].  
These crude peptides were assessed on the pentafluoro phenyl (PFP), diol-hydrophilic interaction 
liquid chromatography (HILIC), and the 2’ ethyl pyridine SFC columns employing technical grade 
CO2 and methanol, which contained 0.2% TFA as well as 5% water as the modifier. Thereafter, post- 
SFC the aforementioned peptides were quantified using liquid chromatography-mass spectrometry 
(LC-MS). 
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2 Materials and methods 
 
2.1 Chemicals and reagents 
 
Methanol, acetonitrile, TFA, and formic acid were purchased from (Merck, Germany). Ultrapure 
water was obtained from a Millipore Milli-Q Gradient (Millipore, USA) water purification system. 
All other solvents and reagents were acquired from Merck (Germany) unless stated otherwise. The 
crude peptides (Table 1) were purchased from AnaSpec, Incorporated (USA).  
 
2.2 LC-MS monitoring 
 
The current study employed LC-MS-2020 (Shimadzu, Japan) for the monitoring of the peptides. The 
instrument consisted of a binary pump, an autosampler, a mass spectrometer, and a NM32LA nitrogen 
generator (Peak Scientific Instruments, United Kingdom). The two mobile phases utilised in the LC-
MS analyses were mobile phase A: Millipore water (Millipore, USA) and mobile phase B: acetonitrile 
(Merck, Germany). These mobile phases both contained formic acid at a concentration of 0.1% (v/v) 
as the ion-pairing agent (Merck, Germany). Injection volumes of 10 μL for the crude tetrapeptide (1 
mg/mL), octapeptide (2 mg/mL) and the nonapeptide (1.5 mg/mL) were used. The tetrapeptide was 
analysed using LC-MS method A with a 5% to 95% gradient profile whereby the acetonitrile was 
ramped up from 5-95% over 18 minutes. The octapeptide and the nonapeptide were analysed using a 
LC-MS method B, whereby the acetonitrile gradient was changed to 5-70% over 22 minutes. The 
flow rates for both methods were 1.0 mL/minute on a stainless steel YMC-triart C18 column (YMC, 
Japan) with the following dimensions; particle size of 5 μm, a 4.6 mm internal diameter, 150 mm in 
length and pore size of 120 Å was used. The nebuliser setting was 1.5 bar, and the desolvation gas 
temperature was set at 250°C. The MS spectra were conducted in positive mode with a mass range 
from 200 to 1500 m/z. 
 
Table 1: Molecular weight and sequences of crude peptides used in this study 
Peptide Peptide length 
Molecular weight 
(Daltons) 
 Peptide 
sequence 
Insulin β chain peptide (15-18) Tetrapeptide (4) 505.7 ± 0.2%  LYLV 
Angiotensin II Octapeptide (8) 1045.2 ± 0.2%  DRVYIHPF 
Insulin β chain peptide (15-23) Nonapeptide (9) 1008.3 ± 0.2%  LYLVCGERG 
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2.3  Columns 
 
Table 2: Physical dimensions of SFC columns employed in this study 
 
Column packing material 
 
Dimensions 
(L x I.D.) mm 
Pore Size 
(Å) 
Particle Size (μm) 
Supplier 
PFP 250 × 4.6 120  5  YMC (Japan) 
diol-HILIC 250 × 4.6 120  5  YMC (Japan) 
2’ ethyl pyridine  250 × 4.6 100  5  Princeton chromatography Inc. 
(USA) 
2’ ethyl pyridine  250 × 10 300  5  Princeton chromatography Inc. 
(USA) 
 
2.4  Solubility of crude peptides  
 
The crude insulin β chain peptide (15-18) (tetrapeptide) and angiotensin II (octapeptide) were 
dissolved in neat methanol to a concentration of 1 mg/mL and 2 mg/mL respectively. However, the 
crude insulin β chain peptide (15-23) nonapeptide needed approximately 96% (v/v) methanol, 4% 
(v/v) water and 0.16% (v/v) TFA for complete solvation at a concentration of 1.5 mg/mL. 
 
2.5  SFC instrumentation  
 
The SFC system (Prep SFC 30, Sepiatec, Germany) was composed of an injector loop, column oven 
(maintained at a temperature of 40°C), a back pressure regulator (BPR) (set at 150 bar), a CO2 pump 
with the pump head maintained at 5C (digital chiller from Polyscience, USA), a high-pressure pump 
for the modifier, and ultraviolet (UV) wavelength detector (set at 220 nanometres (nm)). 50 μL 
injections were conducted for the tetrapeptide (1 mg/mL), octapeptide (2 mg/mL) and the nonapeptide 
(1.5 mg/mL). The mobile phases employed in this study were technical grade CO2 (Afrox, South 
Africa) and methanol, which contained 0.2% (v/v) TFA and 5% (v/v) water (Merck, Germany). A 5-
60% gradient was used, whereby the methanol modifier was initially held for 1 minute, ramped up to 
60% over 6 minutes, and held for a further 5 minutes. The total run time was approximately 13 
minutes. Flow rates of 8 mL/minute were utilised for the 2’ ethyl pyridine (10mm internal diameter 
(I.D.) column); whereas 4 mL/minute flow rates were utilised for the smaller diameter columns (4mm 
I.D.). The following parameters were employed to evaluate the SFC column performances, such as 
reproducibility, peak shapes, efficient SFC peptide separations, and retention factors. After fraction 
collection, the purified peptide samples were spun down using a rotary evaporator (Heidolph, 
Germany) and subsequently stored at 4°C for further analysis. The SFC purifications of the three 
aforementioned peptides were tested in triplicate (n=3), and standard deviations and relative standard 
deviations were conducted. 
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2.6 Peptide recoveries 
 
Multiple injections (50 μL) were run on the Sepiatec Prep SFC 30 system (Sepiatec, Germany). After 
fraction collection, the SFC purified tetrapeptide, octapeptide, and the nonapeptide was carefully 
placed in the rotary evaporator (Heidolph, Germany) to reduce the amount of methanol and 
subsequently freeze-dried overnight using a FreeZone 4.5 litre freeze drier (Labconco, USA). The 
weights of the freeze-dried peptide samples were recorded; the peptide recoveries were determined 
according to the following equation: 
 
Peptide recovery =
 Peptide weight after SFC purification     
Peptide weight before SFC purification
 × 100     
 
3 Results and discussion 
 
The separation of peptides and proteins is dependent on the differential adsorption of the respective 
solutes and their affinities for the stationary phases, with the degree of its binding affinities being 
dependent on the solute’s structures. When a molecule has a higher binding affinity for a particular 
stationary phase, it is retained longer on the column as compared to a molecule with a lower binding 
affinity [19]. The correct selection of an ideal stationary phase is imperative for the separation of these 
analytes. The analyses and purifications of highly polar compounds such as nucleic acids and amino 
acids have been widely avoided, due to poor peak shapes and long retention times, when using 
traditional mobile phases and stationary phases using SFC [16]. Studies have indicated that this 
technique can be utilised to separate and purify strongly polar molecules through the addition of water 
to the modifier phase to improve the molecule's solubility, peak shapes and to aid in a reduction of 
stationary phase interactions [16, 33, 35, 46-48, 50, 51].  
 
This study implemented the use of 5% water with 0.2% TFA to methanol/CO2, which was employed 
as the modifier. Various SFC columns were evaluated to determine the optimal stationary phases for 
the purification of the crude, tetrapeptide [insulin β chain peptide (15-18)], octapeptide [angiotensin 
II], and nonapeptide [insulin β chain peptide (15-23). The peptides were detected and monitored using 
LC-MS analysis before and after the SFC purification. 
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3.1  The LC-MS analyses of the crude tetrapeptide, octapeptide, and nonapeptide  
 
Both the crude tetrapeptide and the octapeptide dissolved well in neat methanol; however, the crude 
octapeptide required more time under sonication and required the addition of 4% water for complete 
dissolution. The crude tetrapeptide (Figure S1), octapeptide (Figure S4), and nonapeptide (Figure S7) 
were analysed via LC-MS before the subjection to SFC purification to confirm their masses and 
purity. The crude tetrapeptide displayed two major peaks (Figure S1); one with a mass of 506.55 m/z 
which correlated to the tetrapeptide (68.36%) (Figures S1 and S2) and the other with a mass of 612.54 
m/z (Figures S1 and S3) that corresponded to an impurity (31.65%) which was as a result of the rink 
amide resin linker by-product [52]. The LC-MS spectra for the crude octapeptide showed one major 
peak (93%) (Figures S4 and S5) with a mass of 1045.66 m/z and several smaller peaks near the 
closest one having a mass of 605.24 m/z corresponding to a double coupling of tyrosine (7%) (Figures 
S4 and S6). The crude nonapeptide (92.59%) had a mass of 1008.64 m/z (Figures S7 and S8) with a 
shoulder peak mass of 1064.75 m/z (Figures S7 and S9) corresponding to the impurity of a tert-
butyloxycarbonyl protecting group (7.41%). With this information in hand, the peptides were tested 
on various SFC columns and conditions for optimal purification. 
 
3.2 The SFC purification of peptides 
 
The crude tetrapeptide, octapeptide, and the nonapeptide were evaluated using the following SFC 
columns; PFP, diol-HILIC, and 2’ethyl pyridine. During the SFC purification of these peptides, there 
were UV wavelength detector noise observed on the SFC chromatograms (Figures 1, 3 and 4), there 
are three possible sources of this noise, i.e., the flow cell which is electronic, mechanical and thermal 
noise which leads to a reduction in sensitivity [53]. The pressure fluctuations refractive indices 
changes due to the BPR of the SFC [54], and the opening and closing of the BPR valve can result in 
the formation of pressure pulses within the system, which were observed in Figures 1, 3, and 4. 
 
3.2.1  SFC column optimisation of the tetrapeptide 
 
The factors that influence the selection of the optimum separation and resolution of peptides are the 
number and the overall distribution of charged groups of a particular peptide, which would affect the 
hydrophobicity, ionisation, and polarisability of the peptide [55]. The tetrapeptide was tested on the 
aforementioned SFC columns (refer to Figure 1 A-D and Table 3). The peak shapes were relatively 
good on the PFP, and the diol HILIC; however, the LC-MS results indicated that the tetrapeptide 
contained a mixture (tetrapeptide and the same impurity from the crude sample) post-SFC 
purification, therefore, indicating that there may be only partial purification occurring (Figure S10).  
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The tetrapeptide was also separated on the 2’ ethyl pyridine 100 Å column yielding the best retention 
factor (5.51) from the three stated columns with good peak shapes, minimal baseline noise, and no 
peak splitting (refer to table 3). Thereafter, the 2’ethyl pyridine column 300 Å (Figure 1-C) was 
selected for further analysis to evaluate the effect of pore size of the stationary phase on the 
purification of the tetrapeptide, refer to Figure 2 and Table 3, post-SFC and was confirmed with LC-
MS analysis (Figures S11 and S12). As can be seen from both the SFC and LC-MS chromatograms, 
the purification was much more efficient with the macro-porous stationary phase. 
 
Figure 1: Represents 50 μL injections of SFC chromatograms of tetra-peptide (1 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl 
pyridine (250 mm × 4.6 mm), D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were tested on a 
gradient mode with a modifier range of 5-60%. 
 
 
    
    
 
A B 
C 
PFP  Diol-HILIC 
column 
2’ Ethyl pyridine 300Å D 2’ Ethyl pyridine 100Å 
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Figure 2: Represents a 50 μL injection of a SFC chromatogram of the tetrapeptide (1 mg/mL) tested 
on a 2’ ethyl pyridine column-based column with the following characteristics; dimensions: 250 mm× 
10 mm, pore size: 300 Å and a particle size of 5 μm. It was conducted on an isocratic mode with a 
modifier range of 20%. 
 
3.2.2 SFC column optimisation of the octapeptide 
 
The crude octapeptide was assessed on the aforementioned SFC columns; (refer to Figure 3 A-D and 
Table 4). The octapeptide was unretained on the PFP column (Figure 3-A). The PFP column is 
comprised of a pentafluoro phenyl group bonded phase, which contained fluorine atoms that have a 
partial negative charge, resulting in significant ionic, π-π, and dipole-dipole interactions [56, 57]. This 
could be attributed to the fact that peptides and proteins comprise of multiple amino acids, which 
consist of basic and acidic side chains, which give the protein a significant amount of charge [58]. The 
diol-HILIC column displayed poor peak shapes and noise on the baselines (Figure 3-B). This column 
is based on layered organic/inorganic hybrid silica and synthesised with a dihydroxy propyl group. 
The composition of the diol-HILIC column is silica molecules joined to oxygen atoms, resulting in 
siloxane bond formations. The remaining unreacted hydroxyl moieties are known as silanols [59]. 
These silanol groups are acidic; as a result, the diol-HILIC column can exhibit cation exchange 
properties [58]. With the diol-HILIC column, secondary interactions can occur between the peptides 
and the stationary phase packing material; this phenomenon is referred to as adsorption effects, which 
contributed to the results obtained in our study [60-64]. The LC-MS results post-SFC indicated the 
presence of a mixture which comprised of the octapeptide and the same impurities from the crude 
sample (Figure S13).  
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Initially, the 2’ ethyl pyridine 100 Å column was employed for the octapeptide, which displayed good 
peak shapes, minimal noise and no peak splitting and this phase was deemed suitable for further 
optimisations (Figure 3-C). We therefore proceeded with evaluating the macro-porous version of this 
column. The 2’ ethyl pyridine 300 Å separated the octapeptide with better peak shapes and retention 
factors of 2.63 and therefore warranted further use (Refer to Figures 3-D, S14, S15 and Table 4).  
 
 
Figure 3: Represents 50 μL injections of SFC chromatograms of the octapeptide (2 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl 
pyridine (250 mm × 4.6 mm), and D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were tested 
on a gradient mode with a modifier range of 5-60%. 
 
3.2.3 SFC column optimisation of the nonapeptide 
 
The crude nonapeptide underwent a similar evaluation on the aforementioned SFC columns (refer to 
Figures 4 A-D, S16-19). The PFP and diol-HILIC columns' separations were inadequate with peak 
splitting, poor peak resolution, and partial separations (refer to Figures 4 and Table 5). Amongst the 
microporous columns, the 2’ethyl pyridine column 100 Å (Figure 4-C) displayed the best retention 
factors and peak shapes with minimal noise (refer to table 5). Therefore, we proceeded to assess the 
effectiveness of the macro-porous 2’ ethyl pyridine 300 Å column (Figure 4-D), which displayed even 
better peak shapes and peak resolution with a retention factor of 2.92, than its microporous 
counterpart.  
    
    
A B 
C 
PFP  Diol-HILIC 
column 
2’ Ethyl pyridine  
                  300Å 
D 2’ Ethyl pyridine 100Å 
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Figure 4: Represents 50 μL injections of SFC chromatograms of nonapeptide (1.5 mg/mL) on the 
following columns: A: PFP (250 mm × 4.6 mm), B: diol-HILIC (250 mm × 4.6 mm), C: 2’ ethyl 
pyridine (250 mm × 4.6 mm), and D: 2’ ethyl pyridine (250 mm × 10 mm). All columns were 
conducted on a gradient mode with a modifier range of 5-60%. 
 
Table 3: Retention factors (k) of the tetrapeptide (1 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, and 
PFP columns.  
 
 
 
 
    
    
A B 
C 
PFP  Diol-HILIC 
column 
2’ Ethyl pyridine 100Å D 2’ Ethyl pyridine  
300Å 
Column k1 k2 SFC conditions Assessment of column 
PFP 3.45 6.53 5-60% gradient Good peak shapes, partial purification, 
the purified sample contained a mixture. 
diol-HILIC 3.79 6.53 5-60% gradient Good peak shapes, however, the 
purified sample contained a mixture. 
2’ ethyl pyridine 
100 Å 
5.51 - 5-60% gradient Good peak shapes, minimal baseline 
noise, and no peak splitting. 
2’ ethyl pyridine 
300 Å 
2.49 2.78 5-60% gradient Poor peak shapes and peak resolution, 
however, the peptide separation 
occurred. 
2’ ethyl pyridine 
300 Å 
2.49 3.83 20% isocratic Good peak shapes and resolution. 
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Table 4: Retention factors (k) of the octapeptide (2 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, and 
PFP columns conducted at 5-60% gradient conditions.  
Column k1 k2 Assessment of column 
PFP Nr Nr Octapeptide was not retained on the column. 
diol-HILIC 4.66 7.22 Noise in the baseline, poor peak shapes, and peak splitting.  
Partial purification as a mixture was present after SFC purification. 
2’ ethyl 
pyridine 
100 Å 
5.85 - Good peak shapes, minimal baseline noise, and no peak splitting 
2’ ethyl 
pyridine 
300 Å 
2.34 2.63 Good peak shapes. Separation of the octapeptide was achieved on this 
column.  
Nr denotes a compound that was not retained on the column. 
 
Table :5 Retention factors (k) of the nonapeptide (1.5 mg/mL) for the 2’ ethyl pyridine, diol-HILIC, 
and PFP columns conducted at 5-60% gradient conditions. 
Column k1 k2 k3 k4 Assessment of column 
PFP 7.90 - - - Good peak shape, however, there 
was only one main peak, and there 
was noise in the baseline. 
diol-HILIC 9.11 9.62 - - Peak splitting and poor peak 
resolution. 
2’ ethyl pyridine    
100 Å 
5.51 6.53 - - Good peak shapes, poor peak 
resolution, minimal noise, and 
good retention factors. 
2’ ethyl pyridine 
300 Å 
2.20 2.63 2.92 3.65 Separation of the nonapeptide 
occurred with good peak shapes 
and peak resolution. Best retention 
factors for the peak of interest of 
2.92. 
 
3.3 SFC recoveries conducted on the 2’ ethyl pyridine column 
 
The 2’ ethyl pyridine column was previously shown to be successful in the SFC separation of peptides 
such as leucine encephalin acetate as well as methionine encephalin acetate, which was reported by 
Tognatelli et al. [25] and proprietary macrocyclic peptides by Ventura et al.[36].  
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In our study, the tetrapeptide, octapeptide, and the nonapeptide confirmed this (Figures 1-C, 3-C, and 
4-C). It is not uncommon that macromolecules such as peptides require wider pore columns to ensure 
the internal surface is accessible to the analyte (pore diameters usually ≥ 300 Å) [65]. Macro-porous 
columns range from approximately 100 to 4000 Å [66]. These columns also allow for better scale-up 
to be conducted as they enable the use of higher flow rates and throughputs, as well as the ability to 
process larger sample volumes, thereby increasing the efficiency of peptide separations. The 
separation of the tetrapeptide [insulin β chain peptide (15-18)], octapeptide [angiotensin II], 
nonapeptide [insulin β chain peptide (15-23)] were reproducible on the 2’ ethyl pyridine column with 
relative standard deviation values of 0-0.02% (see Table 6). The standard deviation and relative 
standard deviation indicated good precision of the method [67]. Therefore, the 2’ethyl pyridine 
column (300 Å) was selected for further evaluation whereby scale-up peptide recovery tests were 
conducted for the three crude peptides (refer to Table 7, Figures S20, S21, and S22). The nonapeptide 
yielded the best recovery of 102%, followed by octapeptide with 100%, and the tetrapeptide with 
80%. The possible reason for the difference in the tetrapeptide recovery from the other two peptides is 
that the tetrapeptide contained more impurities (31.65%) as opposed to approximately 7% impurities 
for both the octapeptide and the nonapeptide. These results correlated to the impurities observed in 
LC-MS results (section 3.1).  
 
Table 6: Reproducibility of retention times (n=3) for the separation of a tetrapeptide (1 mg/mL) 
[insulin β chain peptide (15-18)], octapeptide (2 mg/mL) [angiotensin II], nonapeptide (1.5 mg/mL) 
[insulin β chain peptide (15-23)]. Conducted on a 2’ ethyl pyridine column (250 mm × 10 mm). 
Conducted on a gradient mode with a modifier range of 5-60%. 
Name of peptide Average 
(minutes) 
Standard 
deviation 
(minutes) 
Relative standard 
deviation (%) 
Tetrapeptide 5.83 0,14 0.02 
Octapeptide 6.25 0 0 
Nonapeptide 6.75 0 0 
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Table 7: Represents the recoveries of the tetrapeptide, octapeptide, and the nonapeptide post-SFC 
purification. Peptide recoveries were conducted on the SFC using 5 mg samples (whereby n=1). 
Peptide Peptide length 
Weight 
before SFC (mg) 
 Weight 
after SFC (mg) 
Recovery 
(%) 
 
Insulin β chain peptide (15-18) Tetrapeptide (4) 5   4  80  
Angiotensin II Octapeptide (8) 5   5  100  
Insulin β chain peptide (15-23) Nonapeptide (9) 5   5.1  102  
 
Interestingly, this study had an overall run time of 13 minutes generating 29.24 mLs of waste per run 
as opposed to the conventional analytical RP-HPLC methods of 50 minutes generating approximately 
60 mLs of waste per run [25]. This reduction in run time analysis has implications regarding the 
generation of less waste [68] and therefore decreases the impact on the environment. 
 
4 Conclusion 
 
The SFC purification of the tetrapeptide (LYLV), octapeptide (DRVYIHPF), and nonapeptide 
(LYLVCGERG) on three different phases of SFC columns (PFP, diol-HILIC, and the 2’ ethyl 
pyridine) were assessed on an analytical scale. The purity of the three peptides were detected and 
monitored using LC-MS analyses. The 2’ethyl pyridine stationary phase proved to be optimal for 
these peptides as it displayed good peak shapes and resolution. With this stationary phase, the SFC 
purification methods were reproducible and precise for all three peptides, with observed low relative 
standard deviations ranging from 0-0.02%. The recoveries ranged from 80-102%. It should be noted 
that traditional methods of peptide purification are approximately 50 minutes, while the SFC approach 
decreased the run times to approximately 13 minutes. There was a considerable decrease in the 
amount of solvents employed, making it a greener process. Since there is limited information in 
current literature regarding SFC purification of peptides and proteins, the present study provided an 
imperative method development strategy. The present study included the use of water and TFA in the 
CO2/methanol modifier as well as eliminating the use of toxic acetonitrile and therefore serves as an 
important proof-of-concept starting point for other peptides. Future studies can focus on the use of 
SFC purifications on a larger preparative scale, investigate higher molecular weight peptides/proteins, 
vary the mobile phases, and consider the use of customised columns.  
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5 Summary and conclusion 
 
Protein and peptide biologics are imperative in the pharmaceutical industry as these molecules are 
multifaceted, having anti-cancer, anti-viral, anti-hypertensive, and anti-diabetic properties; these 
biologics can be utilised in the treatment of cancer, arthritis, diabetes, and cardiovascular diseases. 
The present study focused on human insulin and peptides associated with diabetes. Diabetes is a 
major non-communicable disease that occurs when the human body is incapable of effectively using 
insulin. The prevalence of diabetes is placing a substantial burden on our health care system and 
increases the demand for affordable insulin. This creates a massive burden on current insulin 
manufacturers. Consequently, there is a need for scientists to create more affordable methods of 
human insulin purification. The current RP-HPLC purification methods of insulin and peptides are 
problematic with low yields, and employ harsh mobile phases such as acetonitrile that are hazardous 
to the environment. There is a need for a greener process for the purification of these compounds. 
SFC can provide the solution to this problem since SFC purification is a green process since it utilises 
CO2 and methanol as mobile phases, which can be recycled. However, there is limited information 
regarding the SFC purification of biosynthesised human insulin and peptides. Therefore, the aim of 
the present study endeavoured to develop a novel, more efficient approach to the biosynthesis of 
human insulin. Furthermore, this research study also aimed to purify biosynthesised human insulin 
and it also led to the purification of other peptides using SFC.  
 
In chapter two of this thesis, a novel and more efficient method of human insulin biosynthesis was 
developed employing recombinant DNA technology such as polymerase chain reaction techniques, 
which were utilised for the cloning and verification of human insulin in E. coli. The present study 
quantified the biosynthesised human insulin using MALDI-TOF-MS as well as verified it using LC-
MS and protein sequencing. Consequently, the protein sequencing results indicated that the 
biosynthesised human insulin’s sequence was unequivocally proven to be human insulin since the 
protein sequencing was 100% similar to that of human insulin. The biological activity of the crude 
biosynthesised human insulin was evaluated in vitro utilising a MTT assay, and the data indicated that 
the crude biosynthesised human insulin displayed similar efficacy to that of the commercially 
available standard sample of human insulin. The biological activity results were highly significant, 
with a p-value value of < 0.0001. It should be noted that this study was successful in creating an 
innovative, novel, and more affordable strategy for the biosynthesis of human insulin in E. coli. 
Numerous downstream processing costs were eliminated, such as the use of affinity tags for 
purification, renaturation of the protein, enzymatic cleavage of the C peptide and tedious recovery 
steps associated with inclusion body formation. However, the current research study was conducted 
on a laboratory-scale basis; future studies can upscale the current work industrially. 
 
92 
 
In chapter three, a SFC purification method was developed whereby commercially available human 
insulin (standard) and crude biosynthesised human insulin were purified on the SFC. The following 
SFC columns were assessed using standard human insulin: silica, 2’ ethyl pyridine, diol-HILIC, and 
the PFP, to determine the optimum for purification of the biosynthesised human insulin. The PFP 
column yielded the best results which displayed good peak shapes, resolution, retention times, 
retention factors, and the least relative standard deviation in comparison to the other columns. Since 
the aforementioned column was determined to be the best, a column efficiency test was conducted on 
a semi-preparative scale utilising the biosynthesised human insulin yielding an 84% recovery. Herein, 
the detection and quantification of the SFC purified biosynthesised human insulin was conducted 
using protein sequencing, and LC-MS analysis. To determine the effect of the SFC purification on the 
biosynthesised human insulin, a MTT assay was conducted; the results were highly significant with a 
p-value of < 0.0001. Interestingly, the in vitro MTT cytotoxicity results revealed that the biological 
activities of the biological activities of the standard and biosynthesised human insulin derivatives 
were indeed retained post-SFC purification.  
 
In chapter three, numerous challenges were encountered during SFC purification of human insulin, 
such as the development of phase separation peaks, adsorption effects, band broadening, and the use 
of methanol with proteins on the SFC. Therefore, chapter four endeavoured to develop a SFC 
purification method for peptides at an analytical scale. A tetrapeptide [insulin β chain peptide (15-
18)], octapeptide [angiotensin II], nonapeptide [insulin β chain peptide (15-23)] were purified using 
four SFC columns; the PFP, the diol-HILIC, and 2’ ethyl pyridine. The respective peptides were 
monitored using LC-MS analysis. The 2’ ethyl pyridine column was selected for further testing based 
on peak shapes, reproducibility, retention factors, and efficiency of SFC peptide separations of all 
three peptides. Thereafter, recovery tests for the three peptides were conducted on the 2’ ethyl 
pyridine column, and the peptide recoveries were significant, ranging from 80-102%. The research 
results indicated that the present study was successful in the SFC purification of these peptides. As far 
as we are aware, this is one of the first studies to purify biosynthesised human insulin and this 
combination of peptides using SFC technology. 
 
This innovative study can provide a suitable alternative to the traditional RP-HPLC method of 
purifying crude biosynthesised human insulin and peptides. The RP-HPLC purification method is 
time-consuming, with run times of approximately 50 minutes, and utilises hazardous solvents that are 
difficult to dispose of and have a negative impact on the environment. However, in the current 
research study, the SFC purification run times for the methanol soluble peptides was 13 minutes, and 
the biosynthesised human insulin was approximately 10 minutes. As such, the significant reduction in 
run time makes the SFC purification methods of human insulin and peptides less laborious, more 
efficient, and an overall greener process as opposed to the conventional RP-HPLC methods. 
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In conclusion, this innovative application of SFC can be employed as a key platform for the 
purification of peptides and proteins. Protein and peptide biologics are essential in the pharmaceutical 
industry as these biologics have a plethora of therapeutic properties.  
 
Future research studies can use different modifiers, hydrophobic ion-pairing, or chemical modification 
of peptide and proteins to enhance solubility in non-aqueous solvents. Moreover, studies can also 
incorporate the use of custom-made columns to evaluate its effect on a range of proteins and peptides, 
thus paving the way forward to innovative next-generation isolation of novel and current biologics 
using SFC purification. 
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Appendix 1 for Chapter 2 
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Figure S1a: An image depicting a purified PCR product of human proinsulin gene. Lane 1 contains 
the one kb molecular weight marker, and lane 2 contains the purified BamHI and an XhoI ended PCR 
product of human proinsulin gene (345 bp). 
 
 
 
 
Figure S1b: An image displaying colony PCR products of positive transformants obtained from 
clones that contain the pET21b-hPin vector. Lane 1 contains the one kb molecular weight marker, and 
lanes 2-5 contain colony PCR amplicons (345 bp).  
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Figure S2: An image depicting a MALDI-TOF spectrum of standard human insulin as a positive 
control.  
 
 
 
Figure S3: An LC-MS chromatogram illustrating 1 mM IPTG induced biosynthesised human insulin 
sample.  
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Figure S4: A MALDI-TOF standard curve of the insulin standard at 0 ng, 10 ng, 50 ng, 100 ng, and 
1000 ng.  
 
 
 
Figure S5: A peptide spectrum illustrating the protein sequence of standard human insulin, which was 
90% similar to the human insulin sequence derived from Scaffold 1.4.4 software. 
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Figure S6: An SDS-page image displaying the over-expressed GST tagged-human insulin proteins in 
the wild type BL21 (DE3) strain. Lane 1 contains the PageRuler™ pre-stained protein ladder 
(Thermo-Scientific, USA). Lane 2 contains the un-induced wild type strain, and lane 3 contains the 
IPTG induced BL21 (DE3) transformant. 
 
 
 
Figure S7: Illustrating an elution profile of a GST tagged human insulin obtained from the AKTA 
purifier 100-950.  
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Figure S8: Biosynthesised human insulin protein UV spectrum (220-340 nm) obtained from 
NanoDrop™ 2000c. 
 
Table S1: Peptide fragmentation table of crude biosynthesised human insulin, which yielded a 100% 
match to human insulin in the protein database. 
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Figure S1: Represents a LC-MS spectrum obtained from a YMC-Triart C18 (150 mm × 4.6 mm) of 
SFC purified standard sample of insulin (peak1). 
 
Figure S2: Represents a LC-MS spectrum obtained from a YMC-Triart C18 (150 mm × 4.6 mm) of 
the SFC purified standard sample of insulin (peak2). 
 
Figure S3: Represents SFC chromatograms of the A) standard sample of insulin (1 mg/mL) and B) 
biosynthesised sample of insulin (0.52 mg/mL), which were both dissolved in 50 mM Tris-HCl buffer 
and 0.2 % formic acid. A 50 μL injection was tested on a PFP based column (250 mm × 4.6 mm). The 
SFC separations were conducted using an isocratic mode with a 10% modifier. 
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Figure S4: Represents SFC chromatograms of 50 μL injections of the following mixtures: A) DMSO 
and methanol (30:70), B) acetic acid and methanol (7:93), C) formic acid and methanol (6:94) and 
HFIP and methanol (50:50) separated on a PFP column (250 mm × 4.6 mm). The SFC separation was 
conducted using a gradient mode with a modifier range of 5-60%. 
 
Figure S5: Represents SFC chromatograms of standard sample of insulin (0.01 mg/mL) dissolved in 
50 mM Tris-HCl buffer and 0.2 % formic acid: A) 25 μL injection B) 10 μL injection, which were 
separated on a PFP (250 mm × 4.6 mm). The SFC separations were conducted using an isocratic 
mode with a 10% modifier. 
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Figure S6: Represents a LC-MS spectrum obtained from a YMC-Triart C18 (dimensions: 150 mm × 
4.6 mm of the SFC purified standard sample of insulin. 
 
Table S1: Reproducibility of retention times (n=3) for the separation of the standard sample of human 
insulin. A 5-60 % gradient was conducted. 
Column Peaks Average 
(minutes) 
Standard 
deviation 
(minutes) 
Relative 
standard 
deviation 
(%) 
Assessment of column  
GreenSep™ 
silica 
1 3,8 0.1 3.8 Long retention times, poor peak 
resolution and baseline noise 
 2 5.1 0.1 1.5  
 3 5.7 0.1 2.6  
 4 7.9 0.1 1.8  
2’ethyl pyridine 1 8.3 0.3 3.5 Long retention times, baseline noise, 
poor peak shapes and peak 
resolution 
 2 9.5 0 0  
diol-HILIC 1 4,2 0,1 1,7 Poor peak shape and peak splitting 
 2 6,5 0 0  
PFP 1 3,6 0 0 No peak splitting, good peak shape, 
and resolution 
 2 6.9 0 0  
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Table S2: Peptide fragmentation table of standard human insulin, which yielded a 90% probability to 
human insulin in the protein database. 
 
 
Table S3: Peptide table report of the standard human insulin, which yielded a 90% probability to 
human insulin in the protein database. 
 
 
Table S4: Peptide fragmentation table of crude biosynthesised human insulin, which yielded a 96% 
probability to human insulin in the protein database. 
 
 
Table S5: Peptide table report of crude biosynthesised human insulin, which yielded a 96% 
probability to human insulin in the protein database. 
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Figure S1: Represents a LC-MS spectrum obtained of a crude tetrapeptide separated on a YMC-
Triart C18 column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
 
Figure S2: Represents a LC-MS spectrum of a crude tetrapeptide separated on a YMC-Triart C18 
column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
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Figure S3: Represents a LC-MS spectrum of a crude tetrapeptide illustrating the mass of tetrapeptide 
with an impurity separated on a YMC-Triart C18 column (dimensions: 150 mm × 4.6 mm, pore size: 
120 Å and a particle size of 5 μm). 
 
Figure S4: Represents a LC-MS spectrum of a crude octapeptide separated on a YMC-Triart C18 
column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
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Figure S5: Represents a LC-MS spectrum of a crude octapeptide separated on a YMC-Triart C18 
column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
 
Figure S6: Represents a LC-MS spectrum of a crude octapeptide illustrating the mass of octapeptide 
with an impurity separated on a YMC-Triart C18 column (dimensions: 150 mm × 4.6 mm, pore size: 
120 Å and a particle size of 5 μm). 
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Figure S7: Represents a LC-MS spectrum of a crude nonapeptide separated on a YMC-Triart C18 
column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
 
Figure S8: Represents a LC-MS spectrum of a crude nonapeptide separated on a YMC-Triart C18 
column (dimensions: 150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm). 
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Figure S9: Represents a LC-MS spectrum of a crude nonapeptide illustrating the mass of nonapeptide 
with an impurity separated on a YMC-Triart C18 column (dimensions: 150 mm × 4.6 mm, pore size: 
120 Å and a particle size of 5 μm).  
 
Figure S10: Represents a LC-MS spectrum separated on a YMC-Triart C18 (dimensions: 150 mm × 
4.6 mm, pore size: 120 Å and a particle size of 5 μm) of crude tetrapeptide after SFC purification 
using the PFP column. 
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Figure S11: Represents a LC-MS spectrum separated on a YMC-Triart C18 column (dimensions: 150 
mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified tetrapeptide separated 
on the 2’ ethyl pyridine column. 
 
 
Figure S12: Represents a LC-MS spectrum separated on a YMC-Triart C18 column (dimensions: 150 
mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified tetrapeptide using the 
2’ ethyl pyridine column. 
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Figure S13: Represents a LC-MS spectrum separated on a YMC-Triart C18 (dimensions: 150 mm × 
4.6 mm, pore size: 120 Å and a particle size of 5 μm) of crude octapeptide after SFC purification 
using the diol-HILIC column.  
 
 
Figure S14: Represents a LC-MS spectrum separated on a YMC-Triart C18 column (dimensions: 150 
mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified octapeptide separated 
on the 2’ ethyl pyridine column. 
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Figure S15: Represents a LC-MS spectrum separated on a YMC-Triart C18 column (dimensions: 150 
mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified octapeptide separated 
on the 2’ ethyl pyridine column. 
 
 
Figure S16: Represents a LC-MS spectrum separated on a YMC-Triart C18 (dimensions: 150 mm × 
4.6 mm, pore size: 120 Å and a particle size of 5 μm) of crude nonapeptide after SFC purification 
using the diol-HILIC column. 
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Figure S17: Represents a LC-MS spectrum obtained utilizing a YMC-Triart C18 column (dimensions: 
150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified nonapeptide using 
the 2’ ethyl pyridine column. 
 
Figure S18: Represents a LC-MS spectrum obtained utilizing a YMC-Triart C18 column (dimensions: 
150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of a SFC purified nonapeptide using 
the 2’ ethyl pyridine column. 
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Figure S19: Represents a LC-MS spectrum obtained utilizing a YMC-Triart C18 column (dimensions: 
150 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm) of SFC purified nonapeptide using 
the 2’ ethyl pyridine column. 
 
Figure S20: A and B illustrates SFC chromatograms of 50 μL injections of the tetrapeptide which 
was separated on the 2’ ethyl pyridine column with the following characteristics; dimensions: 250 mm 
× 10 mm, pore size 300 Å and particle size of 5 μm, utilizing 20% isocratic conditions. 
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Figure S21: Illustrating a SFC chromatogram of multiple injections of 50 μL of the octapeptide which 
was separated on the 2’ ethyl pyridine column with the following characteristics; dimensions: 250 mm 
× 10 mm, pore size 300 Å and particle size of 5 μm, utilizing a 5-60% gradient.  
 
 
 
Figure S22: Illustrating a SFC chromatogram of multiple injections of 50 μL of the nonapeptide 
which was separated on the 2’ ethyl pyridine column with the following characteristics; dimensions: 
250 mm × 10 mm, pore size 300 Å and particle size of 5 μm, utilizing a 5-60% gradient.  
 
 
 
118 
 
 
 
Figure S23: Represents an SFC chromatogram of a mixture of 2’ Bromo-6-nitro toluene (0.5 mg/mL) 
and N-benzyl benzamide (1.25 mg/mL) of tested on a 2’ ethyl pyridine column with the following 
dimensions: 250 mm × 10 mm, pore size: 300 Å and a particle size of 5 μm. 
 
 
 
Figure S24: Represents an SFC chromatogram of a mixture of 2’ Bromo-6-nitro toluene (0.5 mg/mL) 
and N-benzyl benzamide (1.25 mg/mL) of tested on a 2’ ethyl pyridine column with the following 
dimensions: 250 mm × 4.6 mm, pore size: 100 Å and a particle size of 5 μm. 
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Figure S25: Represents an SFC chromatogram of a mixture of 2’ Bromo-6-nitro toluene (0.5 mg/mL) 
and N-benzyl benzamide (1.25 mg/mL) were tested on a diol-HILIC column with the following 
dimensions: 250 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm. 
 
 
 
Figure S26: Represents an SFC chromatogram of a mixture of 2’ Bromo-6-nitro toluene (0.5 mg/mL) 
and N-benzyl benzamide (1.25 mg/mL) were tested on a PFP column with the following dimensions: 
250 mm × 4.6 mm, pore size: 120 Å and a particle size of 5 μm. 
 
 
 
